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Abstract
Uterine leiomyomata (fibroids) are the most common tumours found in the female 
reproductive system. Whilst many women affected by these benign tumours aie 
asymptomatic, those who do have symptoms may experience a considerable 
reduction in quality of life and impose a significant burden on the National Health 
Seiwice. Surgery remains the established tieatment for women with fibroids 
unresponsive to medical treatment. Hysterectomy is the gold standaid for those 
women who have completed their family whilst myomectomy has been the 
preferred option for women who still wish to conceive in the future.
Uterine aifery embolisation (UAE) is a minimally invasive angiographic 
technique which was fii'st reported in 1995 as an alternative treatment for 
symptomatic fibroids. Since its introduction, more than 100,000 procedures have 
been canied out over the last decade. Studies evaluating the technique are 
encouraging, stating that embolisation is effective in reducing fibroid-associated 
symptoms such as heavy menstrual bleeding, pelvic pain and bulk-related 
problems. As a result, the procedure is becoming increasingly accepted worldwide 
as a uterine sparing alternative for the treatment of symptomatic fibroids. 
Embolisation, however, requires futher evaluation in terms of its safety and 
efficacy in comparison to established therapeutic options for symptomatic 
fibroids. In addition, longer term data is required in order to establish the 
durability of the procedure and potential for associated late presentation of 
eomplications and failures.
The mechanisms by which fibroids develop and grow is still uncleai' to us and 
thus, examination of the uterine vascular network in greater detail may assist 
further in our understanding of the biology of these benign tumours. This may, in
that the results would provide further insight into the aetiology of the post-
turn, assist us in our understanding of the reasons for success and failure of fibroid
therapies such as uterine aifery embolisation
Chapter one provides an introduction to all work in the thesis and initially 
discusses the histology, incidence and epidemiology of uterine leiomyomata. The 
pathophysiology of fibroids is also explored, with particulai' reference to genetic, 
hormonal, vasculai' and growth factor influences. Myométrial and fibroid 
vasculature is discussed in this chapter as well as fibroid symptomatology and the 
aetiology of menorrhagia. Finally, therapeutic options for fibroids including UAE 
are explored as well as the relevance of quality of life assessments in the 
evaluation of UAE and an overview of the currently available compai’ative data on 
embolisation versus surgery in the treatment of symptomatic fibroids.
Chapter 2 presents data from a prospective study evaluating the effect of UAE on 
menstinal blood loss (MBL) and uterine volume. Main outcome measures were 
post-embolisation MBL (objectively measured using the alkaline haematin 
technique) and uterine volume changes. This study concluded tliat UAE is 
associated with a statistically significant reduction in objectively measured MBL 
which is maintained up to 48 months after treatment and a statistically significant 
reduction in uterine volume at six months. ■
Chapter 3 describes subjects and methods used to evaluate the effects of UAE on
health-related quality of life (HRQoL). Using the Short Form 36 (SF 36)
.questionnaire, we concluded that health status is significantly improved at 3 and 6 
months following UAE. In addition, this improvement appears to be maintained 
up to 60 months after treatment. It was also concluded that the observed increase 
in SF 36 scores provides evidence for the efficacy of UAE.
Chapter 4 sets out to investigate the evolution of inflammatory maikers after UAE 
in order to monitor the normal course following the procedure. It was anticipated
embolisation syndrome, a syndi'ome which occurs approximately 7-21 days after 
UAE and is associated with pelvic pain and flu-like symptoms. We found that 
uncomplicated UAE is associated with a significant rise in inflammatory markers, 
specifically white cell count (WCC), C-reactive protein (CRP) and interleukin 6 
(IL-6). The peak rises occur at 3 days with nonnalisation of mai’ker levels at one 
month. No coixelation was found between pain scores at 24 hours and individual 
inflammatory markers at that time. These findings do not assist in providing an 
explanation for the post-embolisation syndrome.
Chapter 5 aims to evaluate and compai'e the safety and efficacy of UAE to 
standard surgical treatments for symptomatic fibroids. This is addressed in the 
setting of a multicentre randomised conti'olled trial. The primary outcome 
measure was health related quality of life at one yeai' as assessed by the SF 36.
presents the data in the form of a case report.
Chapter 7A aims to compai'e human myométrial and fibroid vasculature using 
stereological and moiphometric analysis. A decreasing gradient of vasculai* 
smooth muscle from outer to inner myometrium was found in normal uteri, with 
no coiTesponding gradient in capillary tissue fraction. An association between
I
The study demonstrated there were no significant differences between the
embolisation and surgical arms of the trial, in all components of the SF 36 at one
year. Embolisation, however, was associated with a shorter duration of
'hospitalization and a shorter period of time until resumption of normal activities 
whilst surgery was associated with better symptom scores at one year. Serious
::
adverse events and treatment failures were accounted for in this trial and we
■concluded that the faster recovery after embolisation must be weighed against the 
need for further treatment in a minority of patients.
I
Chapter 6 highlights a late complication after uterine aifery embolisation and
%
vascular luminal size, amplitude and frequency of vessel bending was also
established. Fibroids, however, were found to lack stmctured or muscularized 
vasculature. We concluded that a quantitative gradient exists within the 
myométrial vascular system which is absent in fibroids. These stmctural 
differences between normal and diseased tissue may explain the distribution of 
embolic material and thus the mechanism by which uterine artery embolisation 
achieves its therapeutic purpose.
Finally, Chapter 7B describes experimental work involving vascular perfusion 
techniques and magnetic resonance imaging (MRI) of fresh human utems ex-vivo. 
It was anticipated that this study would demonstrate better resolution of the 
micro vasculai" network of the utems, but we did not find this to be the case.
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Chapter 1
Introduction ÎÏ::!:i
:
1.1 Fibroids
Uterine leiomyomata (fibroids, myomas, fibromyomas) are the most common 
benign tumours of the female genital tract. They can develop at various sites 
within the body, but are most frequently found to affect the uterine myometrium, 
arising from neoplastic transformation of single smooth muscle cells. The vast 
majority are found in the corpus (body) of the uterus (Stewart 2001). Less 
commonly, these benign growths occur in the cervix, uterine ligaments and ovary.
In 1852, Sir James Paget introduced the familiar name “fibroid”, referring to a
'Ùmass that resembles fibrous tissue in both texture and to the naked eye (Sampson 
JA 1912). However, the term does not imply that the tumour is composed of 
fibrous tissue microscopically. In fact, the presence of significant collagen within
r
a leiomyoma is unusual. Nonetheless, the term “fibroid” is both universal in its 
use and understood by all, despite its unscientific origin.
Leiomyomas usually occur within the myometrium (uterine muscle) as well- 
ch'cumscribed, firm, mbbery tumours with a characteristic white whorled 
appearance on cross-section (Shaw, Soutter & Stanton 1992). They are paler than 
the surrounding myometrium and there is usually a very shaip line of demarcation 
between the tumour and the normal uterine muscle (Figure 1). Histologically, 
leiomyomata aie typically composed of spindled smooth muscle cells arranged in 
fascicles with bland, uniform, cigai-shaped nuclei, arranged in interlacing 
bundles, showing little or no mitotic activity. They have abundant eosinophilic 
cytoplasm and the collagenous extracellular' matrix tends to be prominent (Shaw, 
Soutter & Stanton 1992;Stewart 2001).
The size of a fibroid uterus is described in the same fashion as a pregnant uterus, 
in mensti'ual weeks. Unlike the pregnant utei'us, however, it is usually in'egulai' in 
shape (Figure 2).
Figure 1
Cut surface of fibroid uterus -  demonstrates pale appearance of fibroid and line 
of demarcation between normal myometrium and fibroid tissue
Figure 2
Gross specimen of fibroid uterus
Fibroids may be single, but are commonly multiple and can be further classified 
according to their location (Figure 3). The four clinical subgroups that we 
recognise include intramural, sub serosal, submucous and cervical fibroids. Further 
descriptive classification include pedunculated fibroids, where a fibroid is 
attached to the normal myometrium of the uterus by a stalk and the rare parasitic 
fibroid, where the fibroid has developed an alternative blood supply, has separated 
from the uterus and become attached to another structure in the pelvis (Shaw, 
Soutter & Stanton 1992).
Figure 3
Location of fibroids - classification
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developing fibroids (Marshall et al. 1998a).
The true incidence of fibroids is uncertain as many women with these tumours are |
asymptomatic and thus fail to reach clinical attention. Prevalence rates tend to be f
based on rates of diagnosis in symptomatic individuals and following pathological
:assessment of hysterectomy specimens. Whilst such estimates represent the 
morbidity associated with fibroids, it is likely that we significantly underestimate 
the tme prevalence of these uterine lesions. Nonetheless, we are aware that 
fibroids occur in 20-30% of women during reproductive life, rising to 40% in 
women above the age of fifty years who aie still menstruating (Buttram & Reiter 
1981).
Leiomyomata respond to the gonadal steroids oesti'ogen and progesterone and 
their epidemiology parallels life-cycle changes in these reproductive hormones.
These tumours have not been described in prepubertal (Stovall 2001) girls and are 
very rarely seen in adolescents. They are most commonly reported in women 
between the ages of thirty and fifty years and once women reach the menopause, 
fibroids tend to shrink, when both steroid honnone concentrations and menstmal 
cyclicity wane (Stewart 2001). However, some studies have shown an increase in 
risk of fibroids and their associated symptoms with the use of hormone 
replacement therapy (HRT) in the post-reproductive period, especially in those 
women who have taken HRT for 8 years or longer (Schwartz 2001) and have a 
body mass index (BMI) of less than 24 kg/m^ (Reed et al. 2004). Certainly, with 
the use of HRT, they aie less likely to decrease in size after the menopause, but 
larger epidemiological studies are required before we can make definite 1 
conclusions regarding the relationship between fibroids and HRT use during the Imenopause.
Further support of the role of oestrogen and progesterone in the pathogenesis of
■ifibroids is the finding that the eaiiier the age of menai’che, the greater the risk of
■ 1
There aie significant racial differences in the incidence of uterine leiomyomata. 
Afro-Caiibbean women have a 2-9 fold greater risk of developing fibroids and 
tend to present with these tumours at a younger age at the time of diagnosis when 
compared to Caucasian women. Not surprisingly, they subsequently undergo 
definitive treatments such as hysterectomy at earlier ages. In addition, Afro- 
Caribbean women tend to have multiple fibroids, higher uterine weights and aie 
more prone to both anaemia and severe pelvic pain (Kjemlff et al. 1996;Schwartz 
2001;Stewait 2001;Wise et al. 2004). This excess rate of fibroids in the latter :
group of women cannot simply be attributed to a higher prevalenee of risk factors 
and is more likely to be due to a genetic predisposition.
Reproductive factors also influence the risk of fibroids and there certainly appears 
to be a reduction in the chance of developing fibroids in parous (having one or 
more pregnancies extending beyond 24 weeks) women (Luoto et al. 
2000;Mai-shall et al. 1998a;Schwaitz 2001;Stewart 2001;Wise et al. 2004). This 
reduction in risk increases with each liveborn child and decreases with an -
increasing interval of time since last birth (Chen et al. 2001;Luoto et al. 
2000;Marshall et al. 1998a;Schwaitz 2001;Stewart 2001;Wise et al. 2004). The
:
tme incidence of fibroids in pregnancy is unknown although rates of 0.1% - 
12.5% have been reported. Despite the occurrence of red degeneration in eaiiy 
pregnancy, pregnancy has little or no effect on the overall growth of fibroids 
(Cooper & Okolo 2005).
Whilst there appeal's to be an association between the risk of developing fibroids 
and steroid honnone concentrations, studies linking the use of the oral 
contraceptive pill (OCP) and incidence of fibroid formation ar e conflicting (Chen 
et al. 2001;Marshall et al. 1998a;Schwai'tz 2001;Stewai't 2001). It may well be 
that the timing of exposure to these exogenous hormones is the critical event 
which determines whether or not fibroid growth is suppressed or encouraged.
i
Overall, it appears that use of the OCP outwith the teenage yeai's has a protective 
effect against fibroid formation and growth, and this effect is directly proportional 
to the duration of use (Marshall et al. 1998a;Stewart 2001). OCP use and 
pregnancy are both associated with high steroid hormone concentrations, 
suggesting that mechanisms other than hormones, influence the development of 
fibroids.
Depot medroxyprogesterone acetate (MPA) is an injectable progestin-only 
contraceptive. A study in Thailand showed a strong inverse association between a 
history of depot medroxyprogesterone acetate use and the risk of suigically 
confhmed uterine leiomyomata (Lumbiganon et al. 1995). In particulai', the 
reduction in risk was most pronounced among women who had been using depot 
MPA for 5 or more years and who were currently using this contraceptive method. 
Studies correlating the risk of fibroids and obesity aie inconsistent. However, we 
do know that obesity is associated with higher levels of endogenous oestrogen and 
generally, it has been shown that there is a tendency towards an increased risk of 
developing fibroids with increasing BMI (Luoto et al. 2000;Marshall et al.
i
À
1998b;Schwai'tz 2001;Wise et al. 2004), It may also be possible that obesity does 
not dhectly influence the development of fibroids, but rather, promotes the 
development or severity of fibroid -  associated symptoms and / or reduces the 
effectiveness of non-surgical therapeutic options for these tumours (Schwartz 
2001).
It has been reported that there is an association between diabetes and the risk of 
uterine fibroids (Faerstein, Szklo, & Rosenshein 2001). Hyperinsulinaemia and 
insulin-like growth factors (IGFs) have been implicated in the past, for many 
malignant and benign genital tiact pathologies (Macaulay 1992;Yu & Rohan 
2000). We know that insulin resistance and hyperin sulinaemia, both of which ai'e 
associated with clinical diabetes, may also be causes for hypertension,
hyperlipidaeiTÛa and obesity. All of the aforementioned factors may cause 
atherosclerosis (Reaven 1988). Beaiing this in mind, it has been suggested that the 
development of fibroids may share some factors with the development of 
atheromatous plaques which also involves a smooth muscle cell proliferation of 
monoclonal origin (Mashal et al. 1994).
Environmental factors also influence the risk of fibroid development. Independent
*of BMI, smoking appear s to decrease the risk of fibroid development (Pai'azzini et 
al. 1996;Schwartz 2001) as does a high intake of green vegetables and 
independently, a low consumption of red meats (Chiaffaiino et al. 1999;Schwartz 
2001).
■■ ft1.2 Pathophysiology of fibroids
The pathophysiology of fibroids remains poorly understood, although it is clear 
that gonadal steroid hormones and their receptors play a vital role in formation 
and growth of these tumours. Fibroids, themselves, contain both oestrogen and 
progesterone receptors and therefore ai’e responsive to hoimonal stimulation. The 
clinical course of women with symptomatic fibroids strongly suggests that the 
growth of these benign tumours is promoted by both oestrogen and progesterone 
signalling (Maiiro et al. 2004). However, sex steroids ai’e not the only regulators
■'V
of fibroid growth since oestrogen and progesterone levels tend to be noimal in 
almost all women with symptomatic fibroids. As yet, it is not clear as to whether 
sex steroid signalling directly causes the formation of leiomyomata founder cells 
either by transformation of normal myométrial lineage cells or by clonal 
expansion of mesenchymal cells.
Historically, fibroids have not been considered a genetic disease, but now, 
however, we know that genetic predisposition, gene dysregulation and growth
ail
factors important in both fibrotic processes and angiogenesis, also play roles in
% 
;
karyotype (Rein et al. 1991). Of the 40% that have an abnormal karyotype, certain 
consistent patterns are found suggesting that genes important in the formation and 
development of fibroids are likely to be found in these disrupted regions. There is, 
however, major discordance in the karyotypic abnormalities found in fibroids and 
in leiomyosarcomas, suggesting that benign and malignant uterine/myometria 
tumours arise via different pathogenetic pathways (Stewart 2001).
The fhst chromosome aberrations in fibroids were described in 1988 when the 
t(12:14) translocation was shown to be a specific abnormality (Gibas, Griffin, & 
Emanuel 1988;Heim et al. 1988;Turc-Carel et al. 1988), The first gene to be 
discovered in fibroid biology was HMGA2 (previously HMGI-C), dysregulated
9
fibroid aetiology (Stewart 2001).
Initial support of a genetic liability came from twin studies where it was seen that 
in women undergoing hysterectomy for symptomatic fibroids, a strong element of 
heritability occuned (Snieder, MacGregor, & Spector 1998;Stewart & Morton 
2006). Twin studies prior to that established a concordance rate for hysterectomy 
(for all indications) in monozygous twins that is twice that observed in dizygous 
twins (Treloar- et al. 1992). It has also been shown that women with a positive 
family history of fibroids have a 1.5 -  3.5 fold greater risk of developing these 
tumours than those women who do not (Ligon & Morton 2001;Schwartz 
2001;Van Voorhis, Rornitti, & Jones 2002).
It is postulated that there are at least two components to fibroid development; the 
first process which is quite common, involves transformation of normal myocytes 
into abnormal myocytes whilst the second process involves their growth into 
clinically apparent tumours. The latter process occurs via clonal expansion 
(Mashal et al. 1994;Stewart 2001).
We know that 60% of fibroids ai'e chromosomally normal with a 46, XX
1 0
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by translocations between chramosomes 12 and 14. HMGAl (previously 
HMGI(Y)), associated with reaiTangements of chromosome 6, is a related gene, 
also found to have a role in fibroid biology (Stewart & Morton 2006;Williams et 
al. 1997).
Several hereditary syndromes have been reported which involve multiple types of 
smooth muscle tumours, including uterine fibroids (Ligon & Morton 2001). Many 
of these display Mendelian inheritance and thus facilitate relatively 
straightforward approaches to gene discovery for these benign tumours. Presently, 
the most clinically important syndrome known is hereditary leiomyomatosis and 
renal cell carcinoma (HLRCC) owing to its associated risk of malignancy (Kiuru 
et al. 2001;Stewart & Morton 2006). This is an autosomal dominant disease where 
both cutaneous and uterine fibroids ai'e present. Both men and women may 
present with this phenotype and all who ai'e affected ai'e at risk of papillary renal
:
cell cai'cinoma (Launonen et al. 2001). Women, however, appear to have an 
increased risk of renal cell carcinoma when compai'ed to male family members.
They ai'e also at risk of developing leiomyosai'comas pre-menopausally, the 
malignant form of fibroids or leiomyomas (Launonen et al. 2001;Toro et al.
2003).
Reed’s syndrome also known as multiple cutaneous and uterine leiomyomata 
(MCULl) is often reported as an individual syndi'ome, however, it is now clear 
that both Reed’s syndrome and HLRCC are one disease (Stewait & Morton 
2006). Both syndromes became associated when it was found that they involved 
the fumarate hydratase (FH) gene (Alam et al. 2003;Colgan et al. 2003). The latter 
gene codes for the Kieb’s cycle enzyme that converts fumarate to malate. It 
appeal's that fumaiate hydratase acts via a loss of function or tumour suppressor 
mechanism for uterine fibroids. Many different mutations of FH exist, all of 
which result in an absent, tmncated or non-functional protein (Alam et al.
-ft
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2003;Tomlinson et al. 2002). Family members who are affected by fibroids and 
cutaneous lesions should therefore be screened for FH mutation as they are at 
increased risk of developing papillary renal cell cai’cinoma and if female, aie at 
increased risk of developing uterine sarcoma too. CuiTently, however, testing for 
this gene is not commercially available. The FH gene has also been shown to play 
a role in some women with non-syndiomic fibroids (Gross et al. 2004;Lehtonen et 
al. 2004).
Clinical studies aie now beginning to identify DNA polymorphisms that influence 
fibroid risk (polymorphisms are small sequence valuations that are clinically silent 
because there is no amino acid change) and the development of sib-pair analysis 
has allowed us to seai'ch all chromosomes for genes involved in uterine fibroids 
(Stewai't & Morton 2006).
The genetics of uterine fibroids therefore play a vital role in our understanding of 
the pathophysiology of these tumours. We are awai'e that certain treatments for 
fibroids have varying efficacies in individuals and so understanding the different 
phenotypes and genotypes associated with fibroids, is clinically very relevant. 
Abnoimalities in uterine vasculature and angiogenic growth factors are also 
involved in the pathogenesis of uterine fibroids. We are awai'e that the fibroid 
uterus has increased numbers of arterioles and venules and it is likely that 
moleculai' changes ai'e responsible for increased vessel formation and alterations 
in vessel function (Stewart & Nowak 1996).
Leiomyomata aie associated with higher amounts of messenger ribonucleic acid
(mRNA) for basic fibroblast growtli factor (bFGF) - an angiogenic growth factor -
than matched myometrium (Stewai't 2001). bFGF has been shown to stimulate
proliferation of leiomyoma cells in culture (Lee et al. 1998). There are also
differences seen in bFGF receptors of normal and myomatous uteri. In addition, a
reservoir of bFGF protein is stored in the extracellulai' matrix that characterises
11
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fibroids, a finding which is consistent with the role of bFGF as a hepaiin-binding 
growth factor (Mangrulkai* et al. 1995). An abnormal expression of the type 1 
bFGF receptor in the endometrium has also been demons h ated in women with
'fibroid-related bleeding, a finding not seen in women who have normal menstmal 
cycles (Anania et al. 1997). Platelet-derived growth factor (PDGF), another 
angiogenic growth factor, is expressed in similar levels in both noiinal 
myometrium and fibroid tissue. Its expression, however, is increased in the 
myometrium during pregnancy, suggesting tliat PDGF has a role in smooth 
muscle hypertrophy at this time (Hague et al. 2000). Both bFGF and PDGF are 
hepai'in-binding growth factors.
Fibroid growth and development can be viewed as a fibrotic process, where 
specific upregulation of collagen types I and HI can be seen. The latter ai'e major 
components of the extiacellular matiix that distinguishes fibroid tissue from 
normal myometrium (Stewart et al. 1994). As in other fibrotic processes 
tluoughout the body, there is also evidence that transforming growth factor beta 
(TGFp) and granulocyte-macrophage colony-stimulating factor (GM-CSF) may 
be involved in fibroid pathophysiology. Greater amounts of TGFp and TGF(3- 
receptor mRNA and protein have been identified in fibroids than in normal 
myometrium, during the secretory phase of the menstrual cycle (Dou et al. 1996).
In addition, fibroids from women who have been previously treated with a 
gonadotrophin-releasing hormone (GnRH) agonist, a treatment shown to cause 
reduction in fibroid size, have significantly reduced TGF(3 concentrations (Dou et 
al. 1996). It may be that by regulating its own expression and that of TGF(3, GM- 
CSF also induces the tissue fibrosis that we see in fibroids (Chegini, Tang, & Ma
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1.3 Myométrial and fibroid vasculature
and left uterine aiteries penetrate the myometrium giving rise to circumferentially
penetrate the endometrium as small calibre spiral arterioles. Refening exclusively 
to the endometrial vessels as spiral is somewhat of a misnomer because the whole
»
The human uterus is supplied by the uterine, ovarian and vaginal arteries, all of 
which anastomose, giving the organ a rich blood supply (Ramsey 1994). The right
orientated ai'cuate arteries which in turn, branch radially, to form radial aiteries 
(Farrer-Brown, Beilby & Tarbit 1970b). The latter traverse the myometrium and
I
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uterine arteriolar system is in fact tortuous and spiral in character. In contrast, the 
thinner walled venous system, although radial in orientation, does not exhibit 
coiling, but instead, runs a relatively straight course with smaller cross- 
communicating venules ( Farxer-Brown, Beilby & Tarbit 1970c).
Development of the embryonic vascular system results from a continual 
remodelling process which spans the development of small vessels of the primary 
plexus to the formation of large rnuscularized elastic arteries (Drake, Hungerford,
- aft]
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I& Little 1998;Hungerford et al. 1996;Risau 1997). There is eariy distinction 
between arteries and veins, with both linear and radial growth of the vascular' tree 
(Burke, Wang, & Jones 1994;Drake, Hungerford, & Little 1998;Kohnen et al.
2000). Linear- growth facilitates increase in size of the embryo whilst radial 
growth allows both increases in wall thickness and luminal diameter (Drake,
Hungerford, & Little 1998). Microangiography of perfused uterine slices :
demonstrates that spiralling of vessels occurs when axial growth of the vessel
■ f t  
,exceeds that of the surxounding tissue (Farxer-Brown, Beilby & Rowles 1970a;
Far-rer-Brown, Beilby & Tar'bit 1970b). Similar'ly, growth of the endometrial
arterioles, during the menstrual cycle, follows a similar' pattern. Gross vascular
changes occur in the female genital tract during adulthood, and in pregnancy, the
uter-us, with its unusually structured vascular supply, accommodates both stretch
13
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and a vast increase in the lineai’ dimensions of uterine volume (Fleming & Bell 
1997;Gunja-Smith & Woessner 1985).
-
The vasculai' pattern in human myometrium and fibroids has been studied for a 
number of year's and dates back to as early as 1912 (Sampson JA 1912). Fibroid 
vasculature has been studied in a quantitative manner only recently. Prior to this, 
most studies have been qualitative, using a variety of techniques to compaie 
fibroid and normal myométrial vasculature. The ear'liest work in this area focused
= :on describing the structure of fibroid vasculature, using injection of either pigment 
or radio-opaque dyes to outline the vessels (Faulkner 1944;Holmgren B 1938).
These studies demonstrated that the ai’teries supplying the fibroids were dilated in 
appear'ance when compared to those supplying the myometrium, suggesting that 
there was an increase in fibroid vasculature relative to normal uterine tissue.
In the 1970s, Farxer-Brown and colleagues went on to find differences in fibroid 
vasculature in fibroids of different size. They carried out uterine 
macroangiographic studies which initially focused on describing sti*uctural -
arxangements, illustrated by projection images (Fai'rer-Brown, Beilby & Rowles 
1970a; Farxer-Brown, Beilby & Tarbit 1970b; Farxer-Brown, Beilby & Tarbit 
1970c; Farxer-Brown, Beilby & Tarbit 1970d; Farrer-Brown, Beilby & Tarbit 
1971). The earlier studies involved injection of a radio opaque medium into the 
blood vessels of the uterus at both physiological pressure and temperature. 
Radiography of five millimetre thick transverse uterine slices was subsequently 
carxied out. Selected slices were then cut in half or into slices between 75 and 500 
micrometers thick, prior to visualisation under the microscope. This simple 
perfusion technique demonstiated the macro vasculature of the uterus and revealed 
a level of detail that had not been previously demonstrated. It was also used to 
study myométrial fibroids and demonstrated substantial differences between 
normal myometrium and fibroid tissue ( Farxer-Brown, Beilby & Tarbit 1970b;
Faiïer-Browii, Beilby & Tarbit 1970c; Faixer-Brown, Beilby & Tarbit 1970d). 
Arterial vessels of uterine fibroids were typically increased in size, especially in 
association with larger tumours whilst the degree of arterial vascularity was 
variable. It was also observed that small fibroids were usually, although not 
always, less vascular than the surrounding myometrium, whilst larger fibroids 
tended to be more vascular than their surrounding myometrium. In addition, it was 
demonstrated that there was no intrinsic vascular pattern within fibroids. Instead,
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the vascular' ar'rangement of fibroids was thought to represent a localized 
expansion of the vasculature of the corresponding myometrium, with the vessels 
within these tumours orientated in the direction of the muscle cell bundles thus 
accommodating localised proliferation of smooth muscle. We would now interpret 
this as tumour associated angiogenesis. Changes in the vasculature distant to the 
tumour were also seen; in particular, dilated and congested vessels contr'alateral to 
the site of the fibroid were obser'ved.
Unlike studies carxied out thirty year s ear'lier, no venous lakes were demonstrated 
within the normal myometrium ( Far'rer-Brown, Beilby & Tarbit 1970c), but 
dilatation of myométrial veins ar'ound the periphery of a fibroid is a feature 
demonstrated repeatedly by Farxer-Brown and colleagues. Within the inner 
myometrium, close to the endo-myometrial junction, there appears to be a 
relatively “anaemic zone”, first noted by Sampson in 1912. This corresponds to 
newer data which reveal a difference between inner and outer myometrium. The
;network of veins dr-aining the inner myometrium gradually increase in size as it 
runs outwards in a radial direction and joins the plexus of circumferentially 
r-unning arcuate veins ( Fan'er-Brown, Beilby & Tarbit 1970c).
Since then, studies involving corrosion casting and scanning electron microscopy 
(Skopichev & Savitski 1992) have been carried out. This method involves 
injection of a resin which fills the whole vascular' bed, including capillaries.
.ft*
Thereafter, successive corrosion of the tissue unmasks the vascular network which 
is then amenable to examination with electron microscopy. The authors found that 
small fibroids were avasculai' whilst larger ones (3-10 millimetres in diameter) 
were sunounded by a dense and compressed vascular- network with penetration of 
the fibroid tissue by small vessels originating from the fibroid capsule itself. The 
authors also found that the larger the fibroid, the greater the vessel density 
although tills was never greater than that of its surrounding myometrium.
Blood flow and perfusion studies have also been useful in providing further 
information about fibroid vasculature (Forssman 1976a;Forssman 1976b). 
Forssman demonstrated that leiomyomata had significantly lower blood flow than 
the surrounding myometrium, leading to the hypothesis that the lower blood flow 
associated with fibroids may be responsible for the degenerative changes often 
seen in these benign tumours. MRI studies using gadolinium enhancement to 
assess fibroid and myométrial vascularity, confirm the findings of reduced arterial 
perfusion in leiomyomata (DeSouza & Williams 2002). However, not all studies 
concur with the finding of reduced blood flow in fibroids; colour Doppler
ft
ultrasound has been shown to demonstrate an increased blood velocity in the 
uterine arteries of women with fibroid uteri when compar*ed with women with 
normal non-fibroid uteri controls.
More recently, quantitative studies of human uterine and fibroid vasculature have 
been carried out. Moiphometric analysis (i.e. linear- or area measurements made 
on tissue sections) of normal and diseased myométrial tissue suggest that fibroids 
lack the well developed vascular pattern of normal uterine muscle (Casey, Rogers,
& Vollenlioven 2000;Gar-gett et al. 2002;Hague et al. 2000;Poncelet et al. 
2002;Weston et al. 2003). Casey et al carried out a quantitative analysis of 
microvascular- density (MVD) using immunohistochemical techniques which 
involved staining of normal myométrial and fibroid tissue with a variety of
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endothelial cell maikers. They found that the MVD (i.e. vessels per mm^) and
proportional vascular area (proportion of each tissue staining as blood vessel) of
myometrium are greater than that of fibroids, both large and small. Whilst this
does support the blood flow studies of Forssman and de Souza and Williams, it
contradicts the findings of both Sampson and Fairer-Brown et al who
demonstrated increased vasculaiity in large fibroids compared with the adjacent
myometrium. A more recent iimnunohistochemical study also supports the finding
of increased MVD and vascular area in myometrium when compared to fibroid
tissue (Poncelet et al. 2002).
.The three-dimensional architecture of uterine microvasculature may be 
demonstrated with more precision, using stereological analysis. Stereology 
involves estimations of three-dimensional quantities from sections, using spatial 
probes of lines or points. The three-dimensional nature of the microvascular- 
network on cut surfaces of fresh human utei'us has been visualised and 
demonstiated recently (Flamid, Daly, & Campbell 2003), by diffusion labelling.
Using a fluorescent lectin, Ulex Europaeus Agglutinin I (UEA-I), which labels 
endothelial cells by diffusing into tissue and binding to the endothelial cells,
Hamid et al were able to visualise the endothelium of the utems directly. The use 
of an endothelial marker, in this case, UEA-I, highlighted the vascular* differences 
between normal myometrium and fibroid tissue. In particular, fibroids were noted 
to have a less dense distribution of vessels when compared to normal tissue. In an 
extension of this technique, a further study was carried out, using anti-smooth 
muscle antibodies to label the surrounding smooth muscle. The study 
demonstrated that vessels in fibroids were less curwed and had fewer branches, 
when compared to normal myometrium. The fibroids also displayed considerable
variation in the structure of their muscle bundles; this was thought to be due to a
aft
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combination of the plane of visualisation and the pathological chaiacteristics of 
the fibroids themselves (Hamid et al. 2006).
In addition to variations in vascular organization, myométrial muscle also appeal's 
to be layered and displays gradient properties. Discontinuity within the 
myometrium has been demonstrated with the use of MRI and time-lapsed 
ultiasound (de Vries et al. 1990;Kunz et al. 1996;Lesny & Killick 2004). MRI, 
using T2-weighted sequences, demonstrates a distinct inner layer within human 
myometrium although the significance if this observation remains uncleai' (Brown 
et al. 1991). Time-lapsed observations of transvaginal ultrasound recordings 
demonstrate functional differences between inner and outer myometrium. In 
paiticulai', slow peristaltic activity has been shown to emanate from the inner 
myometrium (Lesny & Killick 2004;Masui et al. 2001). These waves vaiy in 
amplitude, dnection and frequency with menstmal cyclicity and are noted to be 
absent from outer myometrium. This functional obsei-vation is consistent with a 
previous report which demonstrated a decreasing gradient of elastin distribution 
from outer to inner human myometrium (Metaxa-Mai'iatou et al. 2002) Whilst 
distinct layering was not obsei-ved, findings certainly suggest that the inner 
myometrium may be less elastic than the outer myometrium. The tissue 
components thought to make up this gradient include vessel wall, perivascular 
tissue and myométrial smooth muscle. All of these obsei-vations suggest the 
existence of distinct inner and outer layers of the human myometrium.
The mechanisms by which fibroids develop and grow remains unclear and thus, 
examination of the uterine vascular network in greater detail may assist further in 
our understanding of the biology of these benign tumours. This may, in turn, assist 
us in our understanding of the reasons for success and failure of fibroid therapies 
such as uterine aitery embolisation.
I
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Whilst the prevalence of uterine fibroids is high, many women with these benign
1.4 Fibroid symptomatology
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tumours aie asymptomatic and do not require medical intei-vention. In fact, it is 
estimated that only 20-50% of women with one or more fibroids will experience 
symptoms that aie directly attiibutable to them. Symptoms associated with these 
tumours can be variable, ranging from mild to severe, causing distress and 
impinging significantly on HRQoL. These include abnoiinal uterine bleeding and 
bulk-related problems such as pelvic pain and pressure, urinaiy frequency and 
constipation. Reproductive dysfunction is also associated with fibroids although 
the exact mechanism by which this occurs is poorly understood.
The incidence and severity of symptoms associated with fibroids is related to the 
location, size and number of lesions present within the uterus, and it is very 
common for an individual to have more than one fibroid present. We aie aware 
that these lesions respond to hormonal stimulation and thus it is not surprising that 
symptoms may vaiy in both severity and chai'acter throughout reproductive life, 
paralleling the growth or shiinkage of these tumours. The duration of time, 
however, in which a change in symptoms occurs, may be of significant length. 
Fibroids tend to be fairly slow growing tumours and rapid growth is always a 
cause for concern. Nonetheless, their malignant potential is less than 1% and thus 
the main aim of treatment is to provide symptomatic relief and improve QoL.
The most commonly reported symptom associated with fibroids is abnormal 
vaginal bleeding. This may be régulai' or iiTegulai'. The two most common 
patterns associated with fibroids, however, are menonhagia and metrorrhagia. 
Menoii'hagia is defined as excessive menstrual blood loss (MBL) in excess of 80 
millilitres (ml) per cycle. This figure represents the 95^ *" percentile, with a mean 
between 30 and 40 ml (Cole, Billewicz, & Thomson I97I;Hallberg et al. 1966a). 
Metrorrhagia refers to prolonged vaginal bleeding. These may occur individually
■ Ï .
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or in combination, and whilst such patterns of bleeding ai’e not diagnostic for 
fibroids, it has been shown that women who present with abnormal uterine 
bleeding ai'e more likely to have a uterine fibroid (Clevenger-Hoeft et al. 1999). 
Excessive bleeding may result in non-deficiency anaemia and all its associated 
problems and can dismpt a woman’s social life significantly. Studies have shown 
that small fibroids are associated with an increased risk of heavy bleeding and this 
risk increases with size. This fibroid-associated bleeding has been demonstrated 
not only with submucosal fibroids (Sulaiman et al. 2004), but also with those that 
ai'e not submucosally located (Wegienka et al. 2003). The pathophysiology of 
fibroid-associated bleeding will be discussed later.
The second most coimnon fibroid-associated symptom is pelvic pain and / or 
pressure. The site and severity of the latter tends to be related to the location and 
size of the fibroid(s). They may compress abdominal and pelvic structures; for 
example, a fibroid originating from the anterior wall of the utems may compress 
the bladder causing urinai'y frequency and / or incomplete bladder emptying 
whilst a posterior wall fibroid may cause backache. Occasionally, large fibroids 
may outgrow their blood supply and in this situation, tissue ischaemia occurs, 
resulting in necrosis which in turn can lead to pelvic pain, often acute and severe. 
Ischaemic necrosis of fibroids is more commonly associated with pedunculated 
fibroids and those which occur during pregnancy. In the latter situation, the 
degeneration process is known as “red degeneration”, where haemorrhage occurs 
within the fibroid, usually causing significant pain (Makar et al. 1989). This pain 
may settle with analgesia and conservative measures, but occasionally, surgical 
intervention is requhed.
The effect of fibroids on reproductive function is difficult to assess and remains 
uncleai'. It has been suggested that fibroids are the sole cause of infertility in only 
2-3% of cases when all other factors have been mled out (Buttram & Reiter
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1981). We are awai'e that both subfertility and fibroids increase in incidence with 
age, and thus it is not surprising that they aie more commonly associated with 
women of advanced reproductive age. Just as increased maternal age Is associated 
with increased chiomosomal abnormalities and subsequent pregnancy loss, 
fibroids ai'e also associated witli early pregnancy loss (Casini et al. 2006;Cooper 
& Okolo 2005a). The effect of a single entity such as fibroids on reproductive
function, however, is difficult to detemiine when overall function involves the 
inteiplay of numerous factors including ovulation, fallopian tube function and 
fertilization. The location of a fibroid or fibroids is important in determining 
tumour-related effects on fertility. Certainly in the past, fibroids with a 
submucosal or intracavity (uterine) component have been implicated, in particular 
(Pritts 2001). Studies looking at in-vitro fertilisation (IVF) outcomes in women 
with known fibroids suggest that fibroid location, followed by size, are the most 
important factors in determining the impact of fibroids on IVF outcomes. Any 
distortion of the endometrial cavity seriously affects IVF outcomes, and 
myomectomy is indicated in this situation. Myomectomy should also be 
considered for patients with lai'ge fibroids, and for patients with unexplained 
unsuccessful IVF cycles (Rackow & Ariel 2005). Other studies looking at the 
effect of fibroids on IVF implantation rates also support the notion that patients 
with intramural fibroids have a lower implantation rate per cycle (Benecke et ai, 
2005).
Despite the limited data on the effects of fibroids on fertility, several mechanisms
by which these tumours aie thought to interfere with normal reproductive function
have been postulated. Fu'stly, they may interfere via mechanical mechanisms. For
example, fibroids occurring in the region of the cornual portion of the uterus may
occlude the fallopian tube causing reduced fecundity. Less commonly, multiple
fibroids may cause bilateral tubal occlusion (Stovall 2001). It has also been
2 1
hypothesised that the rhythmic uterine contractions which facilitate sperm motility 
through the utems may be dismpted and reduced in quality, by large fibroids 
(Coutinho & Maia 1971). Fibroids, either submucous or intramural, may also 
distort the uterine cavity causing reproductive dysfunction. Similaiiy, a large 
fibroid within the uterine cavity, may cause miscaiiiage, intrauterine death, 
premature mpture of membranes, preteiin delivery and / or malpresentation of the 
fetus, simply by mass effect, causing a reduction in the compliance of the
ftpregnant utems.
Implantation of the embryo may also be negatively affected by fibroids. Factors 
responsible for this include impahed gamete transfer, distortion of the uterine 
cavity, impaiiinent of the vascular supply to the endometrium and atrophy or
2005).
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ulceration of the endometiium (Eldai'-Geva et al. 1998). It has also been 
hypothesised that endometrial growth factors may play a role (Benecke et al.
. . f t -
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1.5 Aetiology of fibroid-associated menorrhagia
The pathogenesis of fibroid-associated abnormal uterine bleeding is poorly 
understood although a classic theory, first suggested by Sampson in 1912, states 
that local dysregulation of the vasculai* stiuctures in the utems, is responsible for it 
(Sampson JA 1912). Since then, a number of theories have been postulated (Table
Table 1
Postulated mechanisms for abnormal fibroid-associated bleeding
1. Increased vascularity and blood flow to the utems
2. Increased surface area of endometrium
3. Endometrial ulceration over the surface of a submucous fibroid
4. Interference of normal uterine contractility
5. Compression of myométrial venous plexus by fibroid(s)
platelet-derived growth factor, transforming growth factor-beta, parathyroid 
hormone-related protein and prolactin.
Another mechanism by which a fibroid may cause excessive vaginal bleeding 
includes the rare situation where a pedunculated submucous fibroid prolapses 
though the cer*vix, resulting in ischaemic necrosis and subsequent haemonhage. 
Fibroids, however, do not cause abnormal vaginal bleeding via ovulatory
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More recent evidence, however, suggests that dysregulation of growth factors or 
their receptors in the fibroid utems, which have direct effects on vascular function 
and angiogenesis, provides the molecular mechanism which underlies vascular
■ft;
abnormalities such as menorrhagia (Stewart & Nowak 1996). Factors which may 
prove to be important in this process include basic fibroblast growth factor.
dysfunction as they do not influence ovarian function, ovulation or sex steroid
1.6 Menstrual blood loss estimations
Heavy menstrual bleeding is one of the most common causes of ill health during 
reproductive life. Between the ages of 30 and 49 yeai’s, 5% of women consult
s
synthesis.
"i.
their general practitioner each year* for advice regarding this problem. Excessive 
menstrual blood loss accounts for 12% of gynaecological outpatient referrals and 
previously, 60% of these women were likely to undergo hysterectomy within five 
year's (Myers et al. 2002;Stewar't 2001). Now, however, with the increasing use of 
minimally invasive surgical and non-surgical techniques for the treatment of 
menori'hagia, the hysterectomy rate for this problem has significantly reduced. 
Menori'hagia can be defined both objectively and subjectively. The definition of 
objective menori’hagia is a total measured MBL in excess of 80 ml per cycle. As 
mentioned previously, this definition is taken from population studies carried out 
forty year's ago (Hallberg & Nilsson 1966b). Subjective menorrhagia is defined as 
a complaint or woman’s perception of excessive MBL throughout several 
consecutive cycles during reproductive life.
A number of different methods have been used in the past to estimate menstnral 
blood loss, some subjective and some objective. Most techniques have their' 
limitations, however. It is useful, though, not only to be able to measure MBL for 
the purpose of evaluating a woman’s menstrual symptoms or disease progression, 
but also, to use such estimations as a measure of the efficacy of a treatment (e.g. 
UAE and its effect on fibroid-associated bleeding).
There are a number of subjective methods of MBL estimation. A woman’s own
subjective estimation of her blood loss may be of some use as a screening tool, but
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is not paiticulai'ly accurate in making a diagnosis of menoii'hagia. Studies 
compai'ing this subjective method with more objective techniques found that only 
38-76% of women who complained of heavy MBL actually had objective 
menorrhagia (Chimbha, Anderson, & Turnbull 1980;Rybo 1966;Van Eijkeren, 
Scholten, & Christiaens 1986). Counting the number of days of menstmation, to 
assess MBL is another fahly inaccurate method of quantification. Based on this 
method, a diagnosis of heavy menstmal bleeding is made if menses last more than 
seven days per cycle (Chimbira, Anderson, & Turnbull 1980). It has been 
demonstrated that 78% and 91% of the total MBL of one cycle occurs by the 
second and third days, respectively, of menstmation (Rybo 1966). It has also been 
reported that women with menoii'hagia ai'e more likely to experience the greatest 
volume of blood loss during the first three days of their cycle (Haynes et al.
1977). Not surprisingly, it has been found that only 45% of women who bleed for 
more than seven days, have objective menoii'hagia (Rybo 1966). This test, with its 
low sensitivity, is therefore not deemed to be diagnostic for menorrhagia.
Another method for quantification of MBL is counting the number of sanitaiy 
protection products used during menstmation. Again, this is a poor tool for 
making a definitive diagnosis of menoii'hagia. Firstly, it has been shown that the V
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most important determinants for the number of sanitaiy products utilised were a 
woman’s personal hygiene practices, her frequency of attention to menstmal flow 
and her financial resources (Higham, O'Brien, & Shaw 1990) Secondly, sanitary 
products, depending on the brand, vary widely in teiins of their absorbency, thus 
further influencing the number of products requhed during menstmation.
Weighing sanitaiy protection, by subtracting the weight of the unused from the 
used product, can also facilitate quantification of MBL. Again, this method has its 
limitations, as it accounts for not only menstmal blood, but also, menstmal fluid
€from sources such as endometrial glands and tissue exudates, cei'vical and vaginal
ft;ft
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secretions. It has been shown that the proportion of blood in menstmal fluid varies 
widely amongst women and blood is thought to constitutes only an average of 
36.1% of the total menstmal loss (Fraser et al. 1985). Another drawback of the 
last two methods of MBL estimation is that women may find the process of 
collecting used sanitaiy products unpleasant, inconvenient or unacceptable.
The “menses cup” has also been used to quantify MBL. It involves the use a latex 
seal which completely covers the vagina and collects all menstrual blood and fluid 
without the need for additional sanitaiy protection. There are two types of cup 
described, both of which have proven to be easy to insert into the vagina, but 
difficult to remove whilst successfully retaining all the collected menstmal loss 
(Cheng et al. 1995;Gleeson et al, 1993). In addition, removal of the intact cup 
appeared to be more difficult for those women with a heavy MBL (Cheng et al. 
1995)
The pictorial blood loss assessment chart (PBAC) is a visual representation of 
MBL from which a numerical score is derived (Higham, O'Brien, & Shaw 1990). 
It was first introduced in 1990 and comprises a series of diagrams representing 
light, moderate and heavy soiling of sanitary protection in the form of tampons 
and sanitary towels. In addition, the passage of clots and flooding were accounted
n
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ftfor, the former, by equating the size of clot to that of UK coinage. Increasing
.....scores were assigned for light to heavy soiling of sanitary protection. It was 
reported that when using the PBAC as a diagnostic clinical tool, scores of 100 or 
more diagnosed menorrhagia with a sensitivity and specificity of more than 80% 
(Higham, O'Brien, & Shaw 1990). However, a number of factors were not 
accounted for, including the assessment of extraneous and large volume blood 
loss. In addition, the types of sanitary protection used in the study are now no 
longer available, thus further reducing the accuracy of this tool (Reid, Coker, & 
Coltart 2000).
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The menstmal pictogram is a modified version of the PB AC. Additional icons 
have been created to represent further variation of blood loss on sanitary 
protection, variation in size of blood clot and variation in volume of blood lost in 
the toilet whilst changing sanitary towels and tampons. Distinctions ai'e also made 
between the different levels of absorbency of sanitary protection in order to 
reduce tire inaccuracies of MBL estimations at the higher ranges. Another 
difference from the PBAC is tlrat the score is calculated in millilitres which in 
turn, is equivalent to the actual volume of blood lost (Wyatt et al. 2001). A 
significant positive correlation has been shown between a woman’s ability to 
estimate her blood loss on sanitary protection using this technique and her actual 
objective MBL calculated using the alkaline haematin technique (Hallberg, 
Hogdahl & Nilsson 1966b;Wyatt et al. 2001). Unlike the PBAC, the menstrual 
pictogram has the additional advantage of accounting for estimation of extraneous 
blood loss. By including the latter assessment, the incidence of objective 
menorrhagia increased from 36% to 74% of women who were found to have 
menorrhagia as assessed by the menstmal pictogram. It is important to remember 
that studies validating the use of the menstrual pictogram involved the use of 
standar'dised brands of sanitary wear and it may well be that conversion charts are 
requked when using different brands of sanitary protection.
Menorrhagia is one of the most common causes of anaemia in premenopausal 
women and thus it has been suggested that a full blood count (FBC) may assist in 
the diagnosis of this problem. However, it has been shown that after comparing 
women’s haemoglobin (Hb) levels with their objective MBL measurements (using 
the alkaline haematin technique), anaemia is 74% predictive for having 
menorrhagia (Janssen, Scholten, & Heintz 1995). Haernatocrit, serum iron and 
protoporphyrin levels are inversely related to MBL (Janssen, Scholten, & Heintz
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The management of fibroids very much depends on the symptoms that they cause 
and their effects, if any, on general health and lifestyle. Those women who aie
1995). Nonetheless, all these haematological indices should not be solely relied 
upon to make a conclusive diagnosis or exclusion of menorrhagia.
The alkaline haematin technique is the gold standai’d for objective quantification 
of MBL and was fhst reported in 1964 (Hallberg & Nilsson 1964). It involves 
dilution of sanitaiy protection in a 5% sodium hydroxide solution which extracts 
haem from the menstrual fluid. Whilst very precise, this method is labour 
intensive and time consuming for the clinician. In addition, the collection of used 
sanitaiy protection may be considered unpleasant and cumbersome by some 
women. This technique, therefore, has limited use in clinical practice and tends to 
be reseiwed for use in a reseai'ch setting. It has, however, been modified over time, 
in an attempt to make it simpler to perform (Gannon et al. 1996). Like other 
methods mentioned previously, the alkaline haematin technique fails to account 
for extraneous MBL which can be significant in women with heavy menses. It is 
also a concern that newer sanitaiy products may interfere with the absorbance of 
haem, leading to underestimations of haemoglobin concentrations.
1.7 Treatment of fibroids
asymptomatic or perceive their symptoms to be very mild, do not requne 
definitive treatment. They may be followed up regulaiiy with clinical review and 
serial pelvic imaging. Should any deterioration in symptoms or increase in fibroid 
size occur, however, appropriate tieatment may then be offered.
The traditional treatment of symptomatic fibroids is surgical, namely 
hysterectomy and myomectomy. Hysterectomy ensures complete resolution of 
fibroid-associated menstmal symptoms such as heavy menstmal bleeding and
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dysmenorrhoea. It also guai'antees removal of all fibroids and no recurrence of 
these lesions. Not surprisingly, it is associated with high patient satisfaction rates 
and improvements in overall quality of life. However, it is also associated with 
significant morbidity, a relatively long hospital stay and guarantees infertility 
(Lumsden 2002;Vessey et al. 1992). Hysterectomy may be performed via 
abdominal laparotomy, vaginally or as a lapai’oscopically assisted vaginal 
procedure. Most hysterectomies for fibroids are currently performed by the 
abdominal route. With better training, however, it may be that the vaginal 
approach will be increasingly the choice method of hysterectomy for those 
women with a moderately enlarged fibroid utems.
Myomectomy, whilst aiming to preseiwe fertility, is also associated with
morbidity, a hospital stay of a few days and carries the risk of proceeding to
emergency hysterectomy. In addition, it may further compromise reproductive
potential and provide clinicians with difficulties in long term management owing
to the high recuiTence rate of fibroids and adhesion formation resulting from
previous surgery (Stewart 2001). The procedure tends to be reserved for those
women who wish to retain their fertility. The indications for myomectomy in
infertile women, however, aie contioversial. As mentioned previously, it is
recommended that those infertile women with a fibroid distorting the endometrial
cavity should have the tumour removed. However, the management of those
women with subserosal or intramural fibroids without the distortion of the uterine
cavity, remains uncleai' (Smith & Uhlir 1990;Verkauf 1992). Myomectomy may
be performed as an open procedure (via laparotomy -  the classical method) or
lapai'oscopically, as a lapai’oscopically assisted myomectomy (using a
minilapai’otomy to assist with the laparoscopic procedure). It may also be
performed vaginally or hysteroscopically, using the vaginal route. Whilst the latter
procedure is the gold standard for the treatment of submucous myomas where
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reproductive function is an issue (Kolankaya & Aiici 2006). surgical alternatives 
to the classical method of myomectomy must be evaluated in prospective studies, 
before being recommended for routine use. Currently, most myomectomies tend 
to be performed by the classical method as many women have more that one 
fibroid for resection. Women should also be made awai'e of the conversion rate of 
minimally invasive myomectomy procedures to laparotomy.
Medical treatments such as the levonorgestrel intia-uterine system (Mirena lUS) 
and gonadoti'ophin-releasing hormone (GnRH) analogues have been used to treat 
fibroid-associated menorrhagia and pain, with limited success. The Mkena lUS is 
only useful if the fibroids ai*e small and there is minimal distortion of the uterine 
cavity (Grigorieva et al, 2003). GnRH analogues, whilst proven to be effective in 
shrinking fibroids and greatly improving menstnral symptoms, are limited by thek 
side effect profile, in particular, osteoporosis and unpleasant menopausal 
symptoms (Golan 1996). Even when used in conjunction with addback therapy, 
they ar*e usually only used as a short term treatment solution for symptomatic 
fibroids. Analogues ar*e, however, useful in reducing peri-operative blood loss, 
when administered for short periods of time pre-myomectomy (Lethaby, 
Vollenhoven, & Sowter 2000).
With the evolution of minimally invasive surgical and non-surgical techniques, 
and changing attitudes of both women and clinicians towards uterine preservation, 
the popularity of conservative treatment options has escalated over the last
'
decade. Uterine artery embolisation (UAE) is a minimally invasive angiographic 
procedure which is increasingly being used as an alternative to surgery for 
symptomatic fibroids (Ravina et al. 1995). Other conservative therapies include
-
laparoscopic myolysis (Donnez et al. 2000), MRI guided percutaneous laser 
ablation (Hindley et al. 2002), interstitial laser photocoagulation (Visvanathan et 
al, 2002) and high intensity focused ultrasound energy (Chan et al. 2002;Hesley et
al. 2006;Stewart et al. 2003;Stewai*t et al. 2006). With the exception of UAE, the
latter modalities are relatively new and existing data on their clinical outcomes is 
based on studies that are relatively small and of variable quality. Until their safety 
and efficacies are adequately assessed, they can not be fully validated, and thus 
we are unable to offer these conservative therapies to women routinely.
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1.8 uterine artery embolisation
UAE is a well established minimally invasive procedure performed by
interventional radiologists as an alternative to surgery for symptomatic fibroids. It
has been used in the management of acute pelvic haemorrhage in both obstetric
and gynaecological settings, for more than two decades (Greenwood et al.
1987;Heaston et al. 1979). Its use, however, in the treatment of symptomatic
fibroids, was first reported in France by Ravina, in 1995 (Ravina et al. 1995).
Since then, thousands of UAE procedures have been performed in the UK and it is
now estimated that more than 50,000 have been carried out worldwide. With this
increasing experience of fibroid embolisation, we now have a greater
understanding of the indications, patient selection, pre- and post-procedural
imaging, potential risks and clinical outcomes associated with this technique.
Optimal pre-procedural selection of women is vital for high clinical success rates
and avoidance of complications following UAE. Women who have symptomatic
fibroids in the absence of other pelvic pathology are suitable candidates.
Exclusion of women with adenornyosis is necessary as this particular uterine
pathology responds less well than fibroids to embolisation (Jha et al. 2003). Those
with pedunculated subserosal fibroids should also be excluded owmg to the risk of
ischaemic necrosis and potential for the fibroid to disintegrate and become free in
the abdomen. The latter may be further complicated by causing peritoneal
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irritation, infection and possibly even bowel adhesions (Pelage et al. 2000). 
Confirmed or suspected pelvic infection, an undiagnosed pelvic mass, the 
immunocompromised and severe contrast allergy aie other contraindications. 
Previous pelvic hrradiation or surgery and coagulopathies ai'e relative 
contraindications to the procedure. UAE is paiticulaiiy useful in women who are 
not ideal candidates for surgery. Such patients include the morbidly obese, 
diabetic and those with multiple medical problems. Embolisation is also a useful 
alternative to surgery in women who refuse blood transfusions. These women, 
however, must be counselled regarding the risk of emergency hysterectomy. 
Pregnancy is an absolute contraindication to UAE and until the effects of 
embolisation on reproductive potential have been fully established, the procedure 
should be offered to women who deshe future fertility with caution.
A thorough pre-procedural evaluation should be made on all women prior to 
undergoing UAE. Detailed gynaecological and general medical histories should 
be taken and a gynaecological examination perfonned. All women should have a 
sepaiate consultation with a gynaecologist prior to referral to an interventional 
radiologist. This team approach is the key to a successful outcome. Baseline FBC, 
ferritin levels and a coagulation screen should be performed. A hormone profile 
should also be considered, to provide information about ovaiian reserve. 
Screening for infection with vaginal swabs and a semm c-reactive protein (GRP) 
estimation is only required in women with suspected pelvic infection. 
Endometrial biopsy should be perfonned where appropriate, to exclude 
endometrial hyperplasia and malignancy. For example, women with UTegulai' 
cycles, constant or intermenstrual bleeding and those with prolonged menses or 
heavy menstmal bleeding above the age of 45 years, should all undergo 
endometrial evaluation prior to UAE. This can be done with an outpatient pipelle 
endometrial biopsy or during formal hysteroscopy and endometrial biopsy.
1
Uterine imaging must be performed, firstly to confirm the diagnosis of fibroids 
and secondly, to provide information on their location, size and number. It also 
assists in excluding other pelvic pathology which may be responsible for a 
woman’s symptomatology, hnaging should also assess the viability of the fibroid.
Those tumours with a poor blood supply (e.g. calcified fibroids or degenerative 
fibroids with cystic or haemorrhagic necrosis) are more likely to respond poorly to 
embolisation (DeSouza & Williams 2002;MaiTet et al. 2004b). Wliilst Doppler
ultrasound is used in some centres to fulfil these tasks, most radiologists prefer to
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use contrast-enhanced magnetic resonance imaging (MRI) where available 
(Figure 4a).
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Figure 4a
Pre-embolisation MRI (sagittal T2-wighted image) - nornial sized uterus 
displaced upwards by large cervical fibroid
9
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Figure 4b
Post-embolisation MRI (sagittal T2-wighted image) - note marked reduction in 
cervical fibroid volume and the return of the body of the uterus to its correct 
anatomical site
i
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Bilateral UAE is performed by appropriately trained interventional radiologists 
using a standai'd technique. The procedure is usually carried out under conscious 
sedation although spinal or epidural anaesthesia have been used as alternatives. 
Antiemetics are administered and local anaesthetic is infiltrated into the groin 
prior to percutaneous catheterisation of each of the femoral aiteries. Thereafter, 
both internal iliac arteries are selectively catheterised in turn, allowing 
catheterisation of their respective uterine aiteries (Figure 5a). The latter is 
facilitated by contrast enhancement and digital fluoroscopy (Figure 6a). Once 
catheter placement is confirmed and the vasculai* supply to the fibroids and utems 
demonstrated, multiple small paiticulate emboli in the form of polyvinyl alcohol 
particles (PVA, 500-7lOum in diameter) ai'e then injected into the circulation 
(Figure 5b).
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Figure 5a
Transfemoral catheterisation of the uterine arteries
A #
Cnlholfrr
Fomorai
•III
U % #
Figure 5b
Injection of poly vinyl alcohol particles into the circulation to effect embolisation
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The aim of the embolic material is to selectively occlude both uterine arteries, 
resulting in fibroid devasculaiization and subsequent fibroid shrinkage. Owing to 
the rich pelvic collateral circulation, however, the noiinal myométrial tissue 
revasculaiises. Initially, embolisation was considered complete when there was 
vhtually no demonstrable flow in the distal uterine ai'tery (Figure 6b) (Pelage et 
al. 2000;Ravina et al. 1995;Walker & Pelage 2002).
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Figure 6a
Pre - embolisation angiogram demonstrating simultaneous catheterisation of both 
uterine arteries and the tortuous branches of the uterine arteries supplying the 
fibroid uterus.
-
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Figure 6b
Post - embolisation angiogram showing virtually no demonstrable flow in the 
distal uterine aiteries, thus highlighting that the embolic procedure is complete.
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With increasing experience and the evolution of embolic materials, however, the
degree of aiterial occlusion has become more precise and most radiologists now 
aim to achieve aiterial blushing rather than stasis, where the main aiterial tmnk is 
left patent at the end of the procedure (Pelage et al. 2003). This improved 
precision allows more tai'geted fibroid embolisation with concurrent reduced
unnecessary devascularization of the myometiium and ovaiian vessels.
Individual procedures take approximately 45 minutes to complete and every effort 
is made to keep the total fluoroscopy time and number of image sequences taken 
to a minimum, thus reducing the radiation penalty to the ovaiies. The technique of 
simultaneous catheterisation of both femoral arteries and synchronous 
embolisation of the uterine aiteries may be used to further reduce the duration of 
the procedure and thus, total radiation exposure.
Most patients experience a degree of pain after the second uterine artery is 
embolised. This may be accompanied by nausea and vomiting which responds to 
intravenous antiemetics. Pelvic or abdominal pain usually peaks at six to twelve 
hours post-procedure and it tends to be self-limiting over a further twelve hours. 
For this reason, most women undergo this procedure either as a day case or with a 
single overnight hospital stay where they can receive adequate pain control. A 
cleai' pain management protocol should be in place to facilitate this. A 
combination of oral non-steroidal anti-inflammatory dmgs (NSAIDs) and a 
pai'acetamol-codeine based preparation can provide adequate pain relief post- 
embolisation, but usually, opiate analgesia is requked in the immediate post­
operative period.
It is not uncommon to experience mild lower abdominal cramps for the next seven 
to fourteen days and most women return to normal activities within a couple of 
weeks. They should be made awai'e of all potential complications and side effects 
of the procedure and have an emergency contact number in their possession, prior
j
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to discharge from hospital. Such complications include allergy to the contrast 
medium used during MRI. This is rai*e and occurs in approximately 1% of 
patients. Puncture site complications may also occur (in less than 1% of women) 
following femoral artery catheterisation and these include bleeding, haematoma 
formation and infection. The radiation penalty to the ovaiies appeal's to be 
minimal and as mentioned earlier, oecurs during digital fluoroscopy at the time of 
aiterial catheterisation. Radiologists aim to keep individual fluoroscopic time to a 
minimum with a radiation dose exposure which is similar to that of a baiium 
enema (Glomset et al, 2006;Vetter et al. 2004).
Non-tai'get embolisation or misembolisation may occur either as a result of poor 
procedural technique or due to the presence of aberrant ai'teries. It can cause 
premature ovarian failure and ischemia or necrosis of neighbouring organs 
(Andrews & Binkeit 2003).
The post-embolisation syndrome may occur in up to 10% of women, typically 7- 
21 days after UAE. The syndrome manifests as general malaise, a low grade 
fever, pelvic pain, nausea and vomiting. It is associated with a leucocytosis and is 
often very difficult to distinguish from clinical infection. The syndrome has been 
thought in the past, to result from the release of inflammatory mediators from 
fibroid tissue that has been rendered ischaemic. Management includes adequate 
pain control, hydi'ation, prophylactic antibiotics and reassurance (Walker & 
Pelage 2002).
Transceivical fibroid expulsion has been reported in up to 5% of women (Spies et
al. 2002c). This may occur as a result of uterine shrinkage forcing an intramural
fibroid into the uterine cavity. Expulsion is more common in the presence of
submucous fibroids. Intense abdominal pain can occur just prior to fibroid
expulsion when the cervical canal is obstructed. Occasionally, fibroids are
partially extmded and require hysteroscopic myomectomy for complete removal
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(MaiTet et al. 2004a). Persistent vaginal dischai'ge occurs in approximately 4% of 
women after embolisation and may persist for a few weeks to many months 
(Walker & Pelage 2002). It is due to the expulsion of fibroid necrotic tissue and if 
not self-limiting, may require antibiotic prophylaxis or (hysteroscopic) 
endometrial curettage.
Transient amenorrhea occurs in 5-10% of women after UAE whilst permanent 
amenoiThoea occurs in up to 15% of women above the age of 45 yeai's and in 1% 
of younger women. This premature menopause is usually a consequence of 
embolic material entering the ovaiian ai'terial ckculation via uterine-ovarian 
anastomotic vessels (Goodwin et al. 1999;Spies et al. 1999). The resultant reduced 
ovaiian perfusion eventually leads to ischaemia. All women should be thoroughly 
counselled about this important potential side effect and its consequences, prior to 
undergoing embolisation.
Infection is potentially the most serious complication following UAE (Pron et al. 
2003;Spies et al. 2002c). This may span from mild infection requiring a course of 
oral or intravenous antibiotics, to pelvic sepsis, necessitating emergency 
hysterectomy (Aungst et al. 2004). The latter occurs in less than 1% of cases and 
can be life-threatening. Two cases of death secondary to fatal septic shock 
following UAE have been reported in the literature, to date (De Blok et al. 
2003;Vashisht et al. 1999). Any patient, therefore, presenting with worsening 
pelvic pain, fever, vaginal discharge and leucocytosis following embolisation 
should be admitted as soon as possible. A full infection screen and uterine 
imaging should be performed urgently and the appropriate treatment administered 
promptly.
All women should undergo post-embolisation uterine imaging (Figure 4b), in
order to assess fibroid shiinkage and vascularity. This tends to be performed six
months after the procedure. In addition, women should be reviewed by both
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gynaecologist and interventional radiologist within the six month post- 
embolisation period.
The effect of embolisation on fertility and pregnancy is still not fully established. 
However, successful conceptions, pregnancies and deliveries have been reported 
in women following the procedure (Carpenter & Walker 2005;Pelage et al. 
2000;Pron et al. 2005;Walker & Pelage 2002). It has been suggested by some 
authors that the rates of miscaniage, intra-uterine growth restriction, preterm 
delivery and post-paitum haemorrhage ai'e higher following UAE, all of which ai'e 
complications thought to be due to alterations in uterine blood flow after the 
procedure (Pron et al. 2005). It should also be borne in mind that women 
undergoing embolisation tend to be older and have lai'ge or multiple fibroids, 
factors which also influence fecundity. Reassuringly, MRI of the utems performed 
three to six months post-embolisation reveals rapid revascularization of the 
normal myometrium and an essentially normal appearance of the endometrium 
(DeSouza & Williams 2002;Katsumori, Nakajima, & Tokuhiro 2001 ;Pelage et al. 
2004).
Whilst most women who undergo UAE have completed their family, the 
procedure may be offered to women who wish to retain their fertility with caution. 
The latter group of women must be thoroughly counselled about the potential risk 
of ovaiian failure and be made aware that our data on fertility and pregnancy 
remains limited.
The efficacy of uterine artery embolisation can be detennined by the degree of
improvement or resolution of symptoms. Results from published studies and data
presented at scientific meetings ai'e similar. Most studies divide fibroid-associated
symptoms into excessive menstmal bleeding, pelvic pain and bulk-related
problems. Clinical success rates for treating these complaints range from 81-96%,
70-100% and 46-100%, respectively (Gupta et al. 2006;Katsumori, Kasahai'a, &
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Akazawa 2006;Ravina et al. 1995;Smeets et al. 2006;Spies et al. 1999;Walker & 
Pelage 2002).
As mentioned previously, uterine volume reduction and thus fibroid shrinkage can
be measured by ultrasound or MRI. A 25-60% reduction in uterine volume has 
been reported between three and six months following UAE (Ravina at al. 
1995;Spies et al. 1999;Walker & Pelage 2002). It should be noted, however, that 
reductions in fibroid volume do not always reflect an improvement in clinical 
symptoms.
Three prospective clinical trials comparing the outcome of UAE and hysterectomy 
have been published to date, the fhst two being randomised controlled trials 
(Hehenkamp et al. 2005;Pinto et al. 2003;Spies et al. 2004;Spies et al. 2005).
UAE has been shown to be associated with a shorter hospital stay and recovery 
time when compared to hysterectomy. Satisfaction rates are similar for both 
procedures. Authors state, however, that the higher minor complication rates and 
subsequent higher readmission rates after embolisation, highlight the need for 
cai'eful post-procedural follow-up of women undergoing Üiis procedure.
A prospective randomised controlled trial comparing UAE to myomectomy has 
also been carried out (Maia et al. 2006). The authors concluded that although the 
reproductive outcomes of UAE and myomectomy could not be sufficiently 
evaluated at the time of study publication (more than half of the study population 
were still trying to conceive), initial results indicate that both methods are 
clinically successful in the majority of cases and ai*e not connected with a 
significant number of serious complications.
Longer tenn data on the effects of UAE on symptomatic fibroids is still required, 
with comparisons being made to standard surgical procedures for tliis benign 
condition.
If.
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1.9 Quality of life
Symptomatic leiomyomata can impose restrictions to women in terms of physical,
social and occupational functioning which in turn, can lead to a reduction in
overall HRQoL. The latter, as perceived by the patient, is an important variable in
terms of the outcome of a particular' treatment or inteivention. Quality of life is a
descriptive term that refers to an individual’s emotional, social and physical
wellbeing, and their ability to function in the ordinary tasks of living. HRQoL
analysis aims to measure tire impact of a disease process or subsequent therapy on
these holistic areas within a person’s life. The results of such measures allow us to
inform patients about the burden of their disease, the likely effect of a treatment
and to monitor the success of a treatment from the patient’s perspective.
Despite the prevalence of symptomatic fibroids, little work has been done on the
impact of symptoms on HRQoL until recently. Wlien assessing the severity of a
disease or the efficacy of a therapeutic intervention, clinicians often prefer to rely
upon traditional objective clinical measures. In the case of symptomatic fibroids,
such clinical assessments include objective menstr'ual blood loss measurements,
haemoglobin estimations and radiological measures of fibroid shrinkage.
However, beai'ing in mind that the main aim of treatment for benign disease such
as fibroids is to improve symptoms and HRQoL, the relevance of such objective
measures may be questioned by both patients who wish to decide theh' own plan
of management, and clinicians. Whilst objective measurements aie certainly
useful, subjective assessments of self-perceived health status which take account
of HRQoL have become increasingly important since the 1970s.
Quality of life tools may be divided in to generic and disease-specific categories.
The former may be used to assess the impact of any disease process or
inteivention and include the Short form 36 (SF 36) and EuroQol (Jenkinson,
Coulter, & Wright 1993;Kind P 1996) whilst the latter is designed for assessment
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%iof a disease process or ti’eatment for a paiticular condition. In the case of 
symptomatic fibroids, an example of a disease-specific questionnaire includes the 
more recently developed Uterine Fibroid Symptom and Quality of Life (UFS- 
QOL) questionnaire (Spies et al. 2002a). Quality of life tools should be short, easy 
to administer, acceptable to patients and fully validated.
Using such tools for the assessment of UAE for symptomatic fibroids, satisfaction 
rates of 97% have been reported in most published studies and this tends to 
parallel improvements in symptoms (Gupta et al. 2006;Walker & Pelage 2002). 
Combining the more recent UFS-QOL questionnaire with a generic questionnahe 
such as the SF 36 could provide us with further useful information regarding the 
efficacy of UAE. The fonner questionnaire, however, was not fully validated at 
the commencement of this reseai’ch project and was therefore not used in our 
studies.
.1
1.10 Comparison of UAE to surgery
...
UAE has been evaluated in the short term in a number of studies since its 
introduction in 1995 as a treatment for symptomatic fibroids. In the UK, the 
National histitute of Health and Clinical Excellence (NICE) issued guidance 
regarding the procedure in October 2004. They stated that UAE appealed safe for 
routine use and majority of patients experienced short term symptomatic relief 
(NICE 2004). The safety and efficacy of embolisation compared to other accepted i 
surgical tieatments for symptomatic fibroids, however, has not been evaluated 
until very recently. We therefore aimed to compare UAE to surgery in the setting 
of a randomised contiolled trial (REST trial -  multicenter randomised controlled 
trial comparing embolisation to surgery for the treatment o f fibroids) where the  ^
primaiy outcome measure was quality of life at 1 year. Randomisation has the
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Jadvantage of removing patient selection bias and also has a tendency to yield 
comparable study groups. The REST trial commenced in November 2000 and 
since then, three other randomised controlled trials compaiing UAE to surgery 
have been published (Hehenkamp et al. 2005;Mara et al. 2006;Pinto et al. 2003).
The fkst, published in 2003 by a Spanish group, used a controversial randomised 
consent methodology (Zelen) where women randomized to the hysterectomy arm 
were not informed of the study or of the possible alternative treatment of UAE 
(Pinto et al. 2003;Zelen 1979). The trial was fairly small (11=57) and used length 
of hospital stay as the primary outcome measure. Those in the embolisation aim 
of the trial were found to have a significantly shorter hospital stay whilst the
.complications and satisfaction rates for both UAE and hysterectomy arms of the 
trial were similar'.
The second trial, the EMMY trial was carried out by a Dutch group (Hehenkamp 
et al. 2005). They enrolled 177 women into the study (88 and 89 women were 
treated with UAE and hysterectomy, respectively). The primaiy endpoint of the 
study was elimination of menoii'hagia at a follow-up period of two years, with 
UAE being considered equivalent to hysterectomy if menon'hagia resolved in at 
least 75% of women wiüi no significant differences in major complications 
between the two arms of the trial. Whilst there was no significant difference in 
major complications between the two arms of the trial, the authors found that 
UAE was associated with a significantly higher minor complication rate during 
the first six weeks post-procedure; this in turn, was associated with a higher 
readmission rate. The authors also reported a technical failure rate of 5.3% and a 
high procedural failure rate of 17.3% (a technical failure being regarded as one 
where bilateral uterine ai'teries ai'e not occluded and a procedural failure being 
regai'ded as one where bilateral UAE was not completed for any reason).
-.1
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The third published randomised controlled trial compEued UAE to myomectomy 
in women who wished to preserve their fertility (Mai'a et al, 2006). Sixty thi'ee 
women were recmited into tliis study (30 were treated with UAE and 33 were 
treated with myomectomy) where the mean follow-up period was 17 months. The 
authors found that UAE was associated with significantly shorter procedure 
length, hospital stay and recovery time. However, UAE was also associated with 
higher intervention rates and a lower rate of total symptomatic relief. Both amis of 
the trial did not differ significantly in terms of technical success rates, febrile 
morbidity, complication rates andhoimone profiles at 6 months.
Wliilst the above studies have answered a number of important questions, like any 
trial, they all have them flaws. No trial alone can be taken as a definitive statement 
on the eai'ly outcomes of UAE and hence the REST trial attempts to provide 
further information regaining the safety, efficacy and place of UAE as a uterine- 
sparing modality in the treatment of symptomatic fibroids.
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1.11 Objectives and hypotheses of thesis
The aims of this thesis aie to assess the effect of UAE on objective MBL, uterine 
volume and HRQoL. I also wish to assess the normal course of inflammatory 
mai'kers after uncomplicated UAE, with paiticulai* reference to the post- 
embolisation syndi'ome.
The REST trial (multicenter randomised controlled trial compaiing embolisation 
to surgery for the heatment of fibroids) aims to compaie UAE to surgery in terms 
of safety and efficacy. My role throughout the trial involved recmitment of 
women from hospital gynaecology clinics in the West of Scotland over a period of 
2 yeai's. I was not responsible for analysis of trial data.
Finally, I wish to provide some insight into the pathophysiology of uterine 
fibroids. By examining the vasculature of these lesions and the surrounding 
myometrium, I wish to provide infonnation on the biology of vessel wall 
formation and maturation. Ultimately, I wish to gain some knowledge regaining 
vessel development which in turn, may contribute to the understanding of fibroid 
growth. Owing to time constraints, experimental work and data analysis canied 
out in chapter 7A were canied out by a BSc student.
My hypotheses for this thesis are as follows:-
1. UAE is efficacious in the treatment of symptomatic fibroids in terms of 
sustained reduction in MBL and uterine volume, and improvement in HRQoL.
2. The post-embolisation syndrome is associated with a rise in inflammatory 
markers.
3. UAE is as effective as surgery in terms of safety, efficacy and quality of life.
4. Myométrial vascular integrity is disrupted by the fibroid disease process
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Evaluation of the effect of uterine artery 
embolisation on menstrual blood loss and uterine
volume
a
' '1
2.1 Introduction
The traditional treatment for symptomatic fibroids is surgical and medical 
therapies may be used in a select group of patients, usually in the short-teiTQ.
These therapeutic options, however, are not without di'awbacks and alternative 
treatment modalities are being sought. Uterine artery embolisation (UAE) is a 
useful alternative which has been gaining popularity over the last decade. 
Preliminary obseiwational studies earned out in both Europe and tire USA suggest 
that the procedure is effective in relieving fibroid-associated symptoms in 80-94% 
of women (Goodwin et al. 1999;Pelage et al. 2000;Spies et al. 1999;Walker & 
Pelage 2002). To date, however, none of these studies include objective 
measurements of menstnral blood loss (MBL) pre- and post-embolisation but 
instead, rely on subjective assessment of symptoms. Since the correlation between 
objective and subjective assessment of menstrual blood loss is poor, it is 
important to obtain objective infoiination where possible (Chimbira, Anderson, & 
Turnbull 1980b;Fraser, McCarron, & Markham 1984), especially when evaluating 
a procedure in its early stages.
The definition of objective menorrhagia is a MBL exceeding 80mls/cycle 
(Hallberg et al. 1966b). To make such a diagnosis accurately, precise 
measurement of MBL is required. We therefore decided to carry out a prospective 
observational study to evaluate the effect of UAE on MBL using an objective 
measurement technique. With the use of MRI, we also aimed to evaluate the 
effect of UAE on uterine volume and thus, fibroid shrinkage.
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2.2 Materials and methods
Local ethics committee approval was obtained prior to commencing this 
prospective observational study, Women with an established diagnosis of 
symptomatic uterine fibroids were referred for consideration for UAE from 
hospital gynaecology outpatient clinics in the West of Scotland. They had to have 
experienced either excessive menstmal blood loss, pelvic pain or pressure 
symptoms thought to be due to fibroids; some women had a combination of 
symptoms. The latter was confirmed by a gynaecologist on history taking. The
prior to embolisation and at régulai' intei*vals thereafter (3, 6-9, 12-24, 24-36 and 
36-48 months). Objective measurement of MBL was performed using the alkaline 
haematin technique, a method regai'ded as the gold standai’d for quantification of 
menstrual blood loss (Hallberg et al. 1966b). All menstmal protection from a 
single menses was soaked in a 5% sodium hydroxide solution (for 24 hours) in
women were given detailed written information on the risks, benefits and 
complications of embolisation prior to signing a written consent form agreeing to
Vpaiticipation in our study.
The study group was requested to collect all sanitary protection from one menses
order to extract haemoglobin from menstmal blood. The optical density (OD) of
the alkaline haematin supernatant was then measured using spectophotometry and 
compaied with that of the patient’s own venous blood; the ratio of the ODs 
facilitated calculation of menstmal blood loss.
Prior to UAE, women underwent a pelvic MRI scan, firstly to confirm the
diagnosis of fibroids (including detail of number, site and size) and secondly, to
exclude other pelvic pathology such as adenomyosis and ovaiian disease. This
was repeated at six months post-procedure. Imaging included transverse and
sagittal T l- and T2-weighted images. During the latter pai't of the study, a T l-
gadolinium enhanced sequence was also added to assess uterine vasculai’ity.
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Uterine volume estimations were made in each case, by taking uterine 
measurements in thi'ee dimensions. Using the prolate ellipse equation formula (D1 
X D2 X D3) X 0.5 where D l, D2 and D3 were the transverse, oblique and vertical 
axes measurements of the uterus respectively, the volume was calculated. 
Measurements were calculated by four experienced radiologists, each based in 
one of four Glasgow city hospitals.
Bilateral uterine ai’tery embolisation was performed by appropriately trained 
interventional radiologists using a standaid technique previously described in 
chapter one, section 1.8, page 36.
Since the data for MBL are positively skewed, non-pai'ametric statistical tests 
(Wilcoxon signed rank test) were used for analysis. Data aie expressed as medians 
and ranges. P < 0.05 is considered statistically significant.
2.3 Results
Patients were aged between 29 and 54 years (n = 53). Of 41 women who 
complained of menorrhagia, 36 (88%) had a measured blood loss in excess of 
80ml/cycle. The remaining 12 women who did not complain of menorrhagia 
complained of pressure and / or pain symptoms in the absence of bleeding 
problems. The median MBL was lower at all post-treatment time intervals when 
compared with pre-treatment levels (Table 2).
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Table 2
Menstmal blood loss (ml) pre- and post-embolisation
N Range Median
Pre-treatment 53 9-1339 160
3 months 35 0-767 59
6-9 months 36 0-1283 70
12-24 months 33 0-265 33
24-36 months 19 0-205 18
36-48 months 10 0-66 21
The median reduction in MBL at 3, 6-9, 12-24, 24-36 and 36-48 months was 78, 
61, 125, 126 and 245 ml (95% Cl 64-200, 52-175, 81-226, 74-252 and 142-472), 
respectively. Figure 7a demonstrates menstrual blood loss for individual patients 
pre- and at 3 months post embolsation and Figure 7b highlights the median 
percentage reduction in MBL at all post-treatment time intervals
Figure 7a
Menstrual blood loss for individual patients pre- and at 3 months post- 
embolisation N = 35
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Figure 7b
Median percentage reduction in MBL at all post-treatment time intervals
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All post-embolisation reductions in MBL were statistically significant when 
compared with pre-treatment levels ( 3 months P < 0.001; 6-9 months P < 0.001; 
12-24 months P < 0.001, 24-36 months P < 0.001; 36-48 months P < 0.05).
All but three women experienced reductions in uterine volume following 
embolisation (Figure 8). The median reduction in uterine volume at six months 
post-treatment was 41% (n = 51; 95% Cl 34-49.7; P < 0.001). This did not 
correlate with the change in MBL at that time (Spearman’s rank correlation 
coefficient p = 0.134; P = 0.4).
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Figure 8
Scatter plot demonstrating pre- and post-embolisation uterine volumes for 
individual patients.
[Each dot represents an individual patient; dots lying below the line o f identity 
represent all individuals with a reduced post-treatment uterine volume]
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Six (11%) women underwent hysterectomy during the follow up period; four for 
inadequate reduction of MBL, one for persistent pressure symptoms with 
insufficient fibroid shrinkage and one for a combination of both persistent 
menorrhagia and pressure symptoms. Although a significant reduction in MBL 
occuiTcd in three cases (median 61%; range 43-64%), the post-embolisation blood 
loss was still above the upper limit of normal in two of these cases. Two women 
have undergone myomectomy for insufficient relief of their pelvic pressure 
symptoms, despite good uterine volume reduction.
Seven (13%) women have become amenonhoeic, six of whom have menopausal
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hormone profiles. The median age at the time of menopause was 46 yeai's (range 
= 40-54 years) whilst the median “treatment-menopause” time interval was 4.5 
months (range = 3-36 months). One patient who became amenonhoeic despite 
having a normal hormone profile was presumed to have developed post-infective 
intra-uterine adhesions, thus mimicking the clinical picture of Asheiman’s 
syndrome. None of these women deshed a pregnancy in the future.
Two women have conceived spontaneously at the age of 45 years and 39 year's, 
respectively. The first woman conceived 21 months following UAE and after an 
uneventful pregnancy, she delivered a healthy term baby vaginally. This particular' 
patient experienced a 50% reduction in her MBL 12-18 months after treatment 
and a 51% reduction in her uterine volume at six months post- UAE. The second 
woman conceived 2.5 year's after her embolisation procedure. In this instance, 
UAE was peiformed for bulk-related symptoms only. After an initial 35% 
reduction in uterine volume, her fibroids grew in excess of their pre-embolisation 
dimensions. In view of the risk of major peri-partum haemorrhage, elective 
caesai'ean section with prophylactic placement of balloon catheters in the uterine 
arteries was performed, culminating in an uneventful delivery of a healthy, but 
small for gestational age infant.
2.4 Discussion
The mechanisms whereby fibroids are thought to cause heavy menstmal loss 
remain poorly understood. Hysterectomy, myomectomy and medical tieatments 
all have theh limitations in the treatment of symptomatic fibroids and uterine 
artery embolisation appeal's to provide an efficacious alternative to women who 
wish to avoid surgery.
In the past, MBL has been assessed with the use of pictorial blood loss assessment
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charts and more recently, using menstmal pictograms (Higham, O'Brien, & Shaw 
1990;Wyatt et al. 2001), Previous studies assessing the efficacy of UAE have used 
menstmal diaries and questionnâmes to determine changes in menstrual symptoms 
and most of these report a significant subjective improvement in such symptoms 
following embolisation (Andersen et al. 2001;Brunereau et al. 2000;Chimbira at 
al. 1980;Fraser, McCarïon, & Mai'kham 1984;Goodwin et al. 1999;Hallberg et al. 
1966b;Hutchins, Jr., Worthington-Kirsch, & Berkowitz 1999;Pelage et al. 
2000;Spies et al. 1999;Walker, Green, & Sutton 1999;West and Lunsden 1989). 
Walker and Pelage who were one of the fust clinicians to publish a large 
prospective study evaluating UAE, report an 84% and 79% rate of improvement 
in menstmal bleeding and menstmal pain, respectively (Walker & Pelage 2002). It
is important to remember, however, that there is little or no correlation between 
objective measurement and subjective assessment of blood loss (Chimbira, 
Anderson & Turnbull 1980;Fraser, McCaixon, & Maikham 1984). This 
emphasizes the need for objective tests such as the alkaline haematin technique, 
for the accurate assessment of menstrual bleeding. The problem with the latter 
method, however, is that it is cumbersome and time-consuming for both patient 
and laboratory investigator. Bearing in mind these impracticalities, it is usually 
reserved for use in a research setting such as the one we present here and more 
commonly, subjective assessment of fibroid symptomatology is relied upon. 
Ideally, two menstmal collections would have been collected pre-embolisation in 
our study, but for the reasons stated above, we thought it would be reasonable to 
collect sanitary protection from one menses, prior to treatment. At present, the 
alkaline haematin technique is the only practical means by which an accurate 
diagnosis of menoixhagia can unequivocally be established. However, a precise, 
but simpler method of menstmal blood loss quantification requues to be 
developed in the future,
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The incidence of ovaiian failure was high in our group of predominantly peri- 
menopausal women. All but one who beeame amenoniioeic were over the age of 
45 years and all had completed thek family prior to treatment. Nonetheless, this is 
an important issue that must be discussed with all women considering
3
2.5 Conclusion
Uterine artery embolisation causes a statistically significant reduction in 
menstmal blood loss which in maintained up to 48 months following treatment. It 
is also associated witli a statistically significant reduction in uterine volume at six 
months. This study suggests that embolisation may prove to be an excellent long­
term alternative to both surgical and medical treatments currently available to 
some women with symptomatic uterine fibroids.
6 0
. <
embolisation, paiticulaiiy those who wish to maintain their fertility. In fact, owing 
to the significant risk of ovarian failure following UAE, some gynaecologists and 
radiologists may feel that fibroid embolisation should not be offered to those 
women who desire future fertility.
Elimination of clinical symptoms is the main objective of UAE with uterine 
volume reduction and thus fibroid shrinkage being an additional benefit of 
treatment. It is important to note, however, that symptom relief can occur after 
embolisation in the absence of fibroid shrinkage. In this study, there was no 
relationship found between changes in MBL and uterine volume. Our observation 
reinforces the lack of understanding of the pathophysiology of fibroid-associated 
menoixhagia.
We have shown that UAE is a useful technique for treating uterine fibroids in 
terms of relief of menorrhagia. However, continuing studies with objective MBL 
assessments are required to establish the long term efficacy of this treatment.
V'-'.
Chapter 3
The Short Form 36 and health-related quality of 
life after uterine artery embolisation
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3.1 Introduction
Symptomatic fibroids aie a prevalent pathology amongst our population of 
women causing a significant disease burden to our health services. The chief 
objective of any treatment for benign disease such as symptomatic fibroids is to 
improve HRQoL by alleviating the symptoms associated with the pai’ticulai* 
condition. Despite this fact, little work has been done on the impact of fibroid 
symptoms on HRQoL. Over the last decade, subjective assessments of health have 
gained popularity when evaluating symptoms before or after a particular treatment 
intervention. Bearing this in mind, there is a need for the development and use of 
validated HRQoL tools.
The SF 36 was first inti'oduced in the eaiiy 1990s and it is this tool that I have 
chosen to use for assessment of our group of women undergoing UAE. It is a 
previously validated questionnaire and has been used in a number of ai'eas of 
medicine in the past (Brazier et al. 1992;Jenkinson, Coulter, & Wright 
1993;Kiebzak et al. 2002;Ware J 1993). The questionnahe has the advantage of 
discriminating between symptom severity and health-related quality of life.
The purpose of this prospective observational study was to use the SF 36 to assess 
health status in a gi'oup of women with an established diagnosis of fibroids prior 
to and up to 60 months following uterine ai'tery embolisation (UAE).
3.2 Materials and methods
The SF 36 comprises 36 questions (Appendix 1) assessing 8 dimensions of health 
encompassing physical, emotional and social status (Table 3). A fuither unsealed 
single item exists which assesses changes in the respondent’s health over the past 
year.
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Table 3
Dimensions of Health of the Short Form 36
PF- Physical functioning
RP- Role limitation as a result of physical problems 
BP Bodily pain
GH- General health
VI- Vitality (the frequency of feeling full of energy versus feeling tired)
SF- Social functioning
RE Role limitation resulting from emotional problems
MH- Mental health
Local ethics committee approval was obtained prior to commencing this study. 
Women with an established diagnosis of symptomatic fibroids underwent UAE in 
one of four Glasgow City Hospitals. They were given detailed written information 
on the risks, benefits and complications of embolisation prior to signing a written 
consent form agreeing to participation in our study. Forty seven women aged 
between 29 and 47 years (median 43 years) completed the SF 36 health survey 
prior to UAE, Follow-up was completed by 35, 25, 18, 15 and 12 and 9 women at 
3, 6, 12-24, 24-36, 36-48 and 48-60 months respectively.
All questionnaires were sent to women and returned by post. Patients who did not 
respond initially were sent another copy of the survey with a stamped addressed 
envelope one month later. The questionnaire took approximately 5-10 minutes to 
self-administer.
Normative data were taken from Jenkinson et al (Jenkinson, Coulter, & Wright
1993) for the purpose of compaiison with our group of women with symptomatic
fibroids. Pre- and post-embolisation scores were also compared. For each of the 8
variables of the SF 36, scores were coded, transformed and summed onto a scale
ranging from 0 indicating the worst possible health status, to 100 indicating the
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best possible level of functioning and well being. Paired t-tests were used to 
analyse whether the groups being compaied differed significantly and p < 0.05 
was considered to be statistically significant.
3.3 Results
Figure 9 demonstrates mean SF36 scores for women with symptomatic fibroids 
prior to treatment and compares them with those of age-matched women of the 
normal female population. For each of tlie 8 variables of the SF 36, women with 
symptomatic fibroids achieved lower scores, indicating the disease burden of 
fibroids.
Figure 9
Mean SF36 scores for women with symptomatic fibroids (pre-treatment) and age- 
matched women in the normal population
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Figure 10 displays a radai’ plot compaiing mean pre-treatment scores with those 
obtained from 35 women 3 months following embolisation. Mean scores 
increased in all dimensions of health after treatment indicating subjective 
improvement in health status. Changes in scores were statistically significant in all 
but two dimensions of health (GH and RE).
'i:'i
Figure 10
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Each spoke on the plot represents a specific dimension of health of the 
SF36 (see table 3).
Plots ai'6 read along each spoke from the centre outwai'ds.
Scores aie shown on concentric ckcles beginning with 0 (at centre -  
indicates worst possible health status) and increasing to 100 (outer line -  
indicates best possible health status).
= statistically significant difference at P < 0.05
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Table 4 highlights the mean difference in scores and their respective confidence 
intervals, at this post-treatment time interval.
Table 4
Mean difference in pre- and 3 month post-treatment scores and their respective 
confidence intervals (** = statistically significant)
Mean difference in scores 95% Cl
PF** 8.0 (2.7, 13.3)
RP** 21.1 (4.6, 37.6)
RP** 14.8 (6.0, 23.5)
GH 4.4 (-0.5, 9.2)
yi** 15.4 (8.7,22.1)
SF** 13.9 (5.7,22.1)
RE 12.9 (-4.3,30.1)
MH*-'!' 4.8 (0.2, 9.3)
(see Table 3 for explanation of abbreviations)
At 6 months post-embolisation, 25 women completed the SF 36. Theh mean 
scores obtained at this time interval were compaied with pre-tieatment scores 
(Figure 11). Changes in scores at this time interval were statistically significant in 
6 out of 8 dimensions of health.
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.Figure 11
Radai* plot compaiing mean pre-ti*eatment scores with scores 6 months post- 
embolisation
N=25
Pre-treatment 
6 months post-treatment
At 12-24, 24-36 and 36-48 months (Figure 12) after treatment, 18, 15 and 12 
women respectively, completed the questionnaire; scores increased at these times 
in a very similai' pattern when compaied to previous post-treatment time intervals; 
these increases in scores were statistically significant in 2, 3 and 2 out of 8 
dimensions of health, respectively.
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Figure 12
Radai' plot compaiing mean pre-treatment scores with scores 36-48 months post- 
embolisation
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Finally, at 48-60 months after UAE, 9 women completed the SF 36 and once 
again, mean scores increased from pre-treatment values in all dimensions of 
health. Changes in scores for all dimensions of health at this time interval were 
not statistically significant.
Figure 13 displays mean scores at pre- and all post-treatment time intervals and 
compares these scores with those obtained for the normal age-matched female 
population. It is cleai* that following UAE, scores obtained at all post-treatment 
time intervals not only increase from pre-treatment levels, but also increase to 
levels similar to that of tlie normal female population, suggesting that overall 
functioning and wellbeing has improved towai’ds normality after UAE.
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Figure 13
Mean SF 36 scores at ALL time intervals
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3.4 Discussion
In the past, subjective tools to assess symptomatic fibroids have been aimed 
primaiily towards assessment of menstmal symptoms alone. Such tools include 
menstrual pictograms, menstmal diaries and questionnaires. Whilst these aie 
useful in assessment of menonhagia, neither the non-bleeding symptoms specific 
to fibroids are assessed and nor is the effect of such symptoms on health-related 
QOL.
The advantage of using the subjective SF 36 health survey over the
aforementioned tools is that it takes into account the overall effect of fibroids on
health status. In addition, unlike objective and subjective testing of menstrual
blood loss, the survey is easy to administer and not especially time-consuming for
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patients to complete. Nonetheless, our group of women who completed follow-up 
diminished as time went by due to lack of response or withdi’awal from the study. 
Whilst each questionnaire takes approximately 5-10 minutes to self-administer, 
some women may have perceived that the completion of the questionnaire and the 
additional time taken to airange its postage was too time-consuming to continue 
with. The lack of statistically significant changes in scores with increasing pre­
treatment to post-treatment time inteiwals may be a reflection of the smaller 
numbers of women being assessed as time went by.
A disadvantage of the SF 36 is that it does not include vaiiables which take 
quality and quantity of sleep and sexual function into account. Both sleep and 
sexual activity may be influenced by symptomatic fibroids and therefore aie 
worth considering when assessing both the disease and the influence of a 
ti'eatment intervention on this condition.
The advantage of the UFS-QOL questionnante (Spies et al. 2002a) when 
compaied to the SF 36 is that it not only aims to assess health-related QOL, but 
also, specific menstmal symptoms and bulk-related problems (e.g. urinary
frequency and back ache), both of which are coimnonly experienced by women
with uterine fibroids. The survey has a symptom severity scale comprising 8
questions and a HRQoL scale comprising 29 questions; these scales can be scored
either separately or together thus allowing discrimination between symptom
severity and HRQoL. The UFS-QOL questionnaire has been found to have a low
to moderate correlation with the SF 36 and a moderate to strong correlation with I
the Menorrhagia Questionnaire (Lamping et al. 1998). As far as the SF 36 is
concerned, the “bodily pain” variable of this questionnaire was shown by Spies et
al to have the highest correlation to the UFS-QOL “activities scale”. This suiwey,
however, has only been available for use in the last five yeais (Sirdth et al. 2004)
and was not fully validated at the time of this study. For this reason, we chose to
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3.5 Conclusion
We have concluded from our study that health as assessed by the SF 36 
questionnaire is significantly improved at 3 and 6 months following UAE. This 
improvement appears to be maintained up to 60 months after treatment. We have 
also concluded that the obseiwed increase in SF 36 scores provides evidence for 
the efficacy of UAE.
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use the generic SF 36 questionnaire for assessment of HRQoL in our group of 
women with symptomatic fibroids.
Whilst the SF 36 general health survey does have its limitations, we have shown 
that it is a useful tool for documenting subjective improvements in HRQoL in 
women with symptomatic leiomyomata who have undergone UAE. In addition, 
this questionnaire provides further evidence for the efficacy of UAE as a 
treatment for symptomatic fibroids.
V!
Chapter 4
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Inflammatory response to uterine artery 
embolisation
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4.1 Introduction
Uterine aitery embolisation is associated with significant post-procedural pelvic 
pain in most cases. Whilst this resolves in majority of women within 24-48 hours 
with the use of appropriate analgesia, approximately 10-15% of them experience 
further pain 7-21 days after thek procedure. This pain tends to be accompanied by 
a flu-like illness chamcterised by general malaise, a low grade fever and nausea 
with or without vomiting. We presume that this second episode of significant 
pelvic pain is part of the post-embolisation syndrome (Pelage et al. 2002;Pelage 
et al. 2000;Walker & Barton-Smith 2006;Walker & Pelage 2002). It is similar’ to 
the syndrome which occurs following myocardial infarction (Erzen et al. 
2006;Frangogiannis 2006) and has also been reported after both hepatic artery and 
renal artery embolisation (Bissler et al, 2002;Wigmore et al. 2003).
The aetiology of post embolisation syndrome, however, remains poorly 
understood. It has been postulated that the syndrome results froru a release of 
inflanmiatory ruediators from the fibroids which have undergone ischaemic 
necrosis as a result of UAE. Clinically, it is very difficult to distinguish the 
syndrome from infection and on a number of occasions, unnecessary 
hysterectomy after UAE has been performed for suspected pelvic infection when 
in fact the problem has been the post-embolisation syndr’ome. The latter is usually 
self-limiting and can be treated with adequate analgesia, anti-emetics, antibiotics, 
rehydr’ation and reassurance.
In order to identify and treat this probleru appropriately, we require a better 
understanding of the aetiology of this process. We are aware tlrat an inflammatory 
response occurs in organs other than the uterus after embolisation and therefore 
we set out to investigate the evolution of inflammatory markers after UAE in 
order to monitor the normal course following the procedure. In addition we hoped
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that our results would provide further insight into the aetiology of the post- 
embolisation syndrome.
The inflammatory markers that we chose to measure include white blood cell 
count (WCC), C-reactrve protein (CRP), creatine Idnase (CK), adiponectin, 
interleukin 6 (IL-6), interleukin 18 (IL-18) and tumour necrosis factor alpha 
(TNF-a).
White blood cells, also known as leucocytes, ar'e cells of the immune system 
which defend the body against both infectious diseases and foreign material. 
Several types of white blood cells exist, all of which are produced and derived
from a pleuripotent cell in the bone marrow known as a haemopoietic stem cell.
These cells increase in response to inflammation or infection and ar*e therefore 
useful luarkers of inflammatory processes. C-reactive protein is a protein 
produced by the liver that is present during episodes of acute inflammation or
;■
infection. This protein plays an important role in the body’s immune defence 
mechanism and whilst it is not specific for a paiticular pathology, high levels of 
CRP in blood semm is a general indication of acute inflammation. Creatine kinase 
is an enzyme expressed by various tissue types. It catalyses the conversion of 
creatine to phosphocreatine, consuming adenosine triphosphate (ATP) to 
adenosine diphosphate (ADP), as well as doing the reverse. In skeletal muscle 
especially, and both brain and smooth muscle, phosphocreatine serves as an 
energy reservoir for the rapid regeneration of ATP, the major source of energy in 
biochemical reactions. Elevation of CK is an indication of damage and thus injury 
to muscle.
Adiponectin is a protein hormone secreted specifically by adipocytes. This protein
regulates the metabolism of both lipids and glucose and influences the body’s
response to glucose. Adiponectin has anti-atherogenic and anti-inflammatory
roles, and plasma levels of this hormone are decreased in patients with coronaiy
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4.2 Materials and methods
Local ethics approval was obtained prior to recmiting 13 women into this
prospective observational study. The women were scheduled to undergo UAE for
symptomatic fibroids in one Glasgow city hospital following either direct referral
for the procedure or via the embolisation arm of a randomised controlled trial
comparing UAE to surgery for the treatment of symptomatic fibroids (REST
trial). All of them signed a consent foim agreeing to venepuncture prior to UAE,
24 hours post-procedure and at intervals of 3 days, 7 days and one month
thereafter. The latter three inteiwals required a 20 minute additional visit to the
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artery disease. Interleukin 6 has a major role in the mediation of inflammatory or 
immune responses; it is a pro-inflammatory protein secreted by T-cells and 
macrophages. IL-6 is released in response to infection, bums, trauma and 
neoplasia, and its functions range from key roles in acute-phase protein induction 
to B- and T-cell growth and differentiation. Thus, this protein has direct effects on 
cells and can be agonistic or antagonistic in conjunction with other cytokines. 
Interleukin 18 is a pro-inflammatory cytokine produced mainly by antigen- 
presenting cells. It is an important regulator of both innate and acquired immune 
responses, playing a key role in autoimmune, inflammatory and infectious 
diseases. Finally, tumour necrosis factor alpha, named for its antitumour 
properties, is a cytokine produced primaiily by monocytes and macrophages. It 
plays a critical role in normal host resistance to infection and the growth of 
malignant tumours, serving as an iiumunostimulant and mediator of the 
inflammatory response. Over-production of TNF-alpha has been implicated in a 
number of conditions including septic shock, septicaemia, autoimmune disorders 
and cachexia (progressive wasting).
hospital. Blood was taken in order to measure WCC, CRP and CK. Each of the 
latter was measured by North Glasgow University Hospitals haematology and 
biochemistiy laboratory staff using a standard technique. WCC was measured by 
the Sysmex SE9500 analyser whilst CRP and CK were measured using the Beyer, 
Advia analyser.
Additional blood samples were taken at the aforementioned time inteivals in order 
to quantify levels of IL-6, IL-18, adiponectin and TNF-a. These blood samples 
were spun by centrifuge (Beckman GS-6KR Centrifuge) at 3000 revolutions per 
minute for 10 minutes at 4 degrees centigiade, in order to separate plasma from 
blood cells. This was canied out within two hours of venepuncture. 
Measurements of IL-6, IL-18, adiponectin and TNF-a were then cai’ried out in the 
Vascular Biochemistry Laboratory of North Glasgow University Hospital, by Dr 
Lynne Crawford (Senior Research Technician) and Pauline Watt (Reseai'ch 
Technician).
IL-6 was measured using an R & D kit (19 Bamton Lane, Abingdon Science Pai’k, 
Abingdon, 0X14 3NB, UK) -  catalogue number D6050. IL-18 was measured 
using a MBL kit supplied by R & D (catalogue number 7620). Adiponectin and 
TNF-a were measured using R & D kits (catalogue numbers DRP 300 and 
HSTAOOC, respectively).
Pain scores at twenty four hours were recorded by each patient on a linear 
analogue scale (ranging from 0 [no pain] -  10 [worst possible pain]) and this was 
coiTelated with change from baseline in inflammatory markers at that time 
interval.
Data are expressed as mean ± SD and one-way analysis of variance (ANOVA) 
and paired t-tests were used to analyse results. P < 0.05 was considered 
statistically significant.
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4,3 Results
Ten women had a full set of blood results for all time intervals. Following uterine 
artery embolisation, WCC and CRP values increased significantly from baseline 
pre-treatment levels up to seven days post-procedure. Levels peaked at 3 days 
with average maximums of 11.95 ± 3.50 x lO ' ^ /L and 62.60 ± 43.53 mg / dL, 
respectively; thereafter, levels declined sharply for both maikers, noiinalising 
towards baseline levels at one month (figures 14 and 15).
Figure 14
Mean white cell count (WCC) at all time intervals 
P = 0.012
[eiTor bai's represent standard deviation (SD)]
M ean  WCC At All T im e In terva ls
Pre-WCC 24-WCC 3day-W0C 
T im e In te rv als
7day-WCC Itrth-WCC
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Figure 15
Mean C-reactive protein (CRP) at all time intei*vals
P <  0.0001
M ean CRP At All Tim e Inten/ais
120
100 -
II
g
âI
3day-CRP
Time In te rv a ls
IL-6 levels increased significantly from baseline up to one month post- 
embolisation. Once again, levels peaked at 3 days with an average maximum of 
34.97 ± 32.04 pg / ml, declining thereafter towai'ds baseline levels at one month 
(figure 16).
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Figure 16
Mean inteiieukin 6 (IL-6) at all time intervals
P <  0.0001
Mean IL- 6 At AM Tim e Intervals
80
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24-IL6 7da/-IL6
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T im e In te rv a ls
Creatine kinase, adiponectin, IL-18 and TNF-a levels did not alter significantly 
from baseline after UAE and did not appeal- to show the typical 3-day peak of 
other markers (figure 17,18,19 and 20).
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Figure 17
Mean creatine kinase (CK) at all time intei-vals
P = 0.76
M e a n  CK At All T im e  In te rv a ls
40
20
T im e  I n te r v a ls
Figure 18
Mean adiponectin at all time intei-vals 
P = 0.83
M ean  A d ip o n e c lln  At All T im e  In te rv a ls
lie
Pro Adipo 24  h r a d p o 3  day A dipo 
T im e  I n te r v o ls
7  d a y  A dipo Im tli A dipo
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Figure 19
Mean inteiieukin 18 (IL-18) at all time intervals
P = 0.58
M ea n  IL-18 At All T im e  In te rv a ls
24-L1B 3day-IL1B 7day-IL1S
Tim e In teiv iSs
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Figure 20
Mean tumour necrosis factor alpha (TNF-a) at all time inteiTals 
P = 0.51
M ean  TNF A lpha At All T im e in te rv a ls
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5
7day-TNF
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Figure 21 demonstrates all markers at all time intervals, expressing each marker 
value over time as a percentage of its baseline pre-treatment value.
Figure 21
All markers at all time intervals
2500 1
§  2000 ^
- 4 - WCC 
-<-C R P 
CK
Adiponectin 
-k-IL-6 
- 4 - IL-18 
- ^ T N F  alpha
1500 -OL
1000  -
Time Intervals
Mean pain score at 24 hours was 4.85 ± 3.12 (n -  10). No correlation (Pearson’s 
correlation coefficient) was found between pain score and each of the individual 
inflammatory mai’kers at this time (WCC - r=0.006, P=0.99; CRP - 1^0.037, 
P=0.92; CK - 1^0.203; P=0.57, Adiponectin - r=0.247, P=0.49; IL 6 - i-=0.236, 
P=0.51; IL 18 -1-0.153, P=0.67; TNF alpha -1^0.002, P=l).
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4.3 Discussion
The results of this study indicate that an inflammatory response occurs following 
uncomplicated UAE. However, the peak rises in inflammatory mediators did not 
occur at the time intervals that we expected. Levels of WCC, CRP and IL-6 
peaked at 3 days post-embolisation, with normalisation at one month after 
treatment. To our knowledge, only two studies have been published with regard to 
the inflammatory response after UAE. The first was by a German group who 
measured WCC and CRP in twenty women before and up to five days after 
fibroid embolisation (Voiwerk et al. 2003). The authors concluded that 
uncomplicated UAE is associated with a steep and significant increase in CRP 
between 48-96 hours after treatment, with a decline in levels thereafter. They also 
demonstrated a mild increase in WCC, peaking at 72 hours and normalising by the 
fifth day post-embolisation. Both these trends in inflanuuatory maikers were 
thought not to indicate an infected fibroid.
More recently, maikers of muscle ischaemia, necrosis and inflammation following 
UAE have been studied by Banu et al (Banu et al. 2007). A number of markers 
were quantified, including CK, ischaemia-modified albumin (IMA) and CRP. The 
study group were randomised to either the UAE treatment arm (n=14) or the 
abdominal myomectomy aim (n= ll), and blood maikers were measured before, 
iimuediately after, 18-24 hours and six weeks after treatment, hikeeping with our 
study, no significant change was seen in CK levels after UAE. However, whilst a 
rise in CRP was seen 24 hours after embolisation, the rise in this inflammatory 
mediator was significant only six weeks after treatment. No significant rise in 
IMA was observed after UAE. The authors concluded that no significant 
ischaemia or necrosis occurs in association with UAE, suggesting that the 
procedure does not significantly damage the myometrium.
%
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The findings from our study do not support our initial hypothesis that the post- 
embolisation syndi'ome results from a release of inflaimuatory mediators from 
fibroids which have undergone ischaemic necrosis as a result of UAE. If this was 
the case, we would have expected to see significant rises or peaks in inflammatory 
mai'kers 7-21 days after embolisation, in women who experienced flu-like 
symptoms and pelvic pain at this time interval. Thus an alternative explanation 
must exist for the pathogenesis of the post-embolisation syndi'ome. The lack of 
coiTclation that we found between levels of pain experienced by women and 
individual inflanuuatory markers 24 hours after UAE also suggests that fibroid 
ischaemia and inflaimuation are not the only causes of pelvic pain experienced by 
women after embolisation.
All women in our study experienced variable degrees of pelvic pain in the 
iruruediate few hours and days after treatment. As expected, ruost women were 
discharged 24 hours after their procedure and reported both resolution of pain 
over 7 days and resumption of normal activities within two weeks of 
erubolisation. Four women complained of mild flu like symptoms (in the absence 
of a temperature) and pelvic pain 7-21 days after UAE; their syruptorus were 
thought to be due to tlie post-embolisation syndrorue, but inflammatory ruarkers 
were norrual at the tirue when they reported their symptoms. One woman, 
however, required adiuission for severe pelvic pain 7-10 days after UAE and 
again, three-four weeks post-procedure. Her clinical symptoms also occuiTed in 
the absence of a temperature. White cell count and CRP levels were persistently 
elevated at these times. It was presumed that this woman’s symptoms (which fully 
resolved six weeks after UAE with conservative measures and reassurance) were 
due to the post-embolisation syndrome.
This study had a number of limitations. The number of women recruited was 
fauiy small as it was difficult to find women who were willing to undergo
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additional blood tests necessitating extra hospital visits. Also, some women who 
initially agreed to entry into this study, subsequently defaulted from a number of 
the necessai'y hospital visits; these women had to be excluded from the study. It
4.5 Conclusion
Uncomplicated UAE is associated with a significant rise in inflammatory mai'kers, 
specifically WCC, CRP and IL-6. The peak rise occurs at 3 days with 
normalisation of marker levels at one month. No conelation was found between 
pain scores at 24 hours and individual inflammatory maikers at that time.
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may have been useful to measure our chosen maikers more frequently over a one 
month period and it may well be that measurement of inflammatory markers other 
than those that we chose to analyse, would have provided us with additional 
information regaiding the course of uncomplicated UAE and the post- 
embolisation syndrome.
Chapter 5
Comparison of uterine artery embolisation with 
surgery for the treatment of symptomatic 
leiomyomata
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1.
i5.1 Introduction
Uterine aitery embolisation is starting to become accepted as a routine uterine- 
sparing modality for the treatment of symptomatic fibroids. Nonetheless, there is 
still a need to compare it to established and accepted therapeutic options for this 
condition. Whilst most published studies are encouraging, few present 
compai'ative data assessing the safety and efficacy of the procedure. The REST 
trial is a Scottish multicenter randomised controlled trial comparing embolisation 
to surgery as a treatment for fibroids. It aims to address these issues with a 
primary outcome measure of quality of life at one yean Long term follow-up is 
due from 2007.
.1;..
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5.2 Materials and methods
The trial commenced in November 2001 in seven hospitals in Scotland, but later 
expanded to include a total of 27 hospitals in the United Kingdom, two of which 
were based in England. Recniitment was completed in May 2004 and twelve 
month follow-up was completed in September 2005. Ethics committee approval 
was granted by the Multicentre Research Ethics Committee and local approval 
granted at every centre. All subjects provided written informed consent. The 
potential recririts were provided with written information which described the 
study and the potential risks of ti'eatment including the unknown effects of 
embolisation on any subsequent pregnancy. A trial coordinator was appointed to 
supeiwise the trial and 4 research nurses and a reseai'ch fellow in gynaecology 
(myself), caiiied out recruitment and follow-up of patients within the 26 centres 
participating in the trial. Appropriately trained inteiwentional radiologists earned 
out the embolisation procedures, with referral to specialist centres from district 
units when requued. They used a standard technique for embolisation, as
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described in chapter 1, section 1.8, page 36. Surgery was in the form of either 
hysterectomy or myomectomy and was carried out at each local centre.
Patients were recruited at the local hospital gynaecology clinics. Women were 
eligible for entiy into the trial if they had one or more fibroids > 2cm in diameter 
which could be adequately imaged using MRI and caused sufficient symptoms 
(e.g. menoiThagia, pelvic pain and pressure) to justify surgical treatment. 
Exclusion criteria included a contiuindication to MRI, severe allergy to iodinated 
contrast media, the presence of subserosal pedunculated fibroids, other pelvic 
pathology such as endometriosis or adenomyosis, cuiTent pregnancy, recent or 
ongoing pelvic inflammatory disease and chronic illness. No restrictions were 
made regarding the size or number of fibroids.
All women undeiwent a basehne MRI scan prior to treatment, with T2 sagittal, T2 
coronal oblique and T1 sagittal images being taken. During the mid to latter stages 
of the trial, gadolinium enhancement was used; the aforementioned protocol for 
imaging was therefore carried out before and after blood vessel enhancement. 
Imaging was repeated at 6 months following treatment in those women who were 
recruited into the embolisation arm of the trial, using the same protocol. All 
women who requhed further intervention following either UAE or myomectomy 
were asked to have a further MRI scan prior to the intei-vention. The number of
fibroids, the diameter of the largest fibroid and uterine volumes (measured using 
the standai’d technique described in chapter 2, section 2.2, page 54) were recorded 
together with the presence of any other abdomino-pelvic pathology.
Those patients whose MRI findings fitted the trial criteria were then randomised 
into one of two study groups according to a computer generated schedule 
(permuted blocks) held by the study co-ordinator. Randomisation was stratified by 
centre and used a 2:1 ratio with twice as many women being allocated to the new
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treatment (embolisation) gi'oup as to the surgical group. This allowed us to obtain 
as much infonuation as possible on the novel procedure with minimal reduction in 
statistical power of the study.
The method of surgery i.e. hysterectomy or myomectomy was left to the 
discretion of the individual operator who took into consideration the woman’s 
reasons for wishing to preserve her fertility and / or utems and MRI findings. 
Both operations were included since viitually all surgical procedures for fibroids 
aie performed by the open route, allowing appropriate compaiison of outcomes. 
Likewise, the precise technique for embolisation was not specified and left to the 
discretion of the operator although both uterine arteries had to be embolised and 
the particle size of the embolic agent was standardised at 500-710 microns. Most 
centres used non calibrated polyvinyl alcohol (PVA) (Cook Inc, UK) and Tnifill 
(Cordis Ltd, UK) although latterly a few patients were embolised with Bead 
Block (Biocompatibles UK Ltd, Suixey, UK).
The primaiy outcome measure was quality of life at 12 months as assessed by the 
SF 36. As mentioned previously, this generic tool has been previously validated in 
women with menoiThagia (Jenkinson, Peto, & Coulter 1996). Secondaiy outcomes 
included quality of life as measured by the EuroQol 5D QoL questionnaire (an
instrument used to measure preferences for certain health outcomes), a tool with a
range of scores paralleling those of the SF 36. Other secondaiy outcomes were the
time taken to reach functional milestones after the procedure, an 11 point
symptom score (-5 [mai'kedly worse] to + 5 [markedly better]) and a satisfaction
score asking whether the women would recoimnend her treatment to a friend
(recorded as either yes, no or unsure). Pain score at 24 hours was also measured
using a 10-point lineai’ analogue scale with documentation of the analgesic
requhement at that time. The presence or absence of complications was also
recorded as well as ti'eatment failures, defined as the need for subsequent
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intei*vention for symptom cooti'ol, including hysterectomy or repeated 
embolisation.
Complications were graded using the Society of Inteiwentional Radiology (SIR) 
classification, recoimuended in their '‘Standards of Practice” (Goodwin et al. 
2001), as follows:
Society of Inteiwentional Radiology Complication Grading
1 No therapy, no consequence
2 Nominal therapy, no consequence, includes overnight admission 
for obseiwation only
3 Requhes therapy, minor hospitalisation (<48 hours)
4 Requires major therapy, unplanned increase in level of care, 
prolonged hospitalisation (>48 hours)
5 Peiiuanent adverse sequelae
Grades 1-2 and 3-5 were subsequently grouped as minor and major complications, 
respectively. The categorization of complications was carried out by two of the 
investigators independently -  one a Consultant Gynaecologist and the other, a 
Consultant Radiologist. In discordant cases, the worse grade was used.
Major serious adverse events (SAEs) included any major complication, life 
threatening events, hospitalisation (initial or prolonged), disability, an inteiwention 
requhed to prevent permanent impainuent or damage and death. SAEs also 
included treatment failures requhing readmission for repeat embolisation or 
surgery.
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A fixed analgesia protocol was suggested for the UAE aim of the trial which 
included rectal diclofenac, pai'cnteral morphine or diamorphine, benzodiazepine 
sedation and antiemetics; all preparations were given 1 hour prior to embolisation. 
Further opiates were administered during the procedure as single doses and over 
the next 24 hours, women received analgesia via a patient controlled analgesia 
pump (PCA).
Surgical patients all had then* procedures performed under general anaesthetic. 
Post-operative pain was managed by the administration of opiates via a PC A 
pump according to the standaid procedures in that unit. The total opiate consumed 
within the first 24 hours was recorded for both groups.
After dischai'ge from hospital, outcome measures were assessed at 1, 6, 12, and 21 
months, and annually thereafter. Twelve month results aie presented here, with 
the exception of major adverse events requiring hospitalisation and subsequent 
inteiwention for treatment failure, which are reported up to September 2005 
(maximum follow-up 58 months).
Statistical analysis was based on intention to treat (i.e. patients were analysed in 
the group to which they were randomly assigned, iiTespective of the treatment 
they actually received). Analysis of covaiiance was used to compare quality of 
life scores (SF36 and EuroQol) between groups, adjusting for baseline values. 
Two sample t- and Mann Whitney tests, and chi-squaied tests were also used to 
make compaiisons between groups, the fonner for continuous data and the latter 
for categorical data.
The original power calculation required the enrolment of 200 patients to give a 
power of 90% to detect a difference of 10 points in the SF36 score at 12 months 
(the primaiy end-point) at a 0.05 significance level. Owing to the slower than 
expected recmitment process, however, the decision was subsequently made to
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reduce the power of the study to 80%; this required a total sample size of 150 
paiticipants.
An independent data monitoring coimuittee reviewed the results and any SAEs 
every 12 months. They followed the highly conservative Haybittle-Peto approach 
which requires a significance level of less than 0.001 in the compaidson between 
groups before making any recommendations to terminate the trial prematurely 
(Jennison & Turnbull 2000).
The study was funded by the Chief Scientist’s Office of the Scottish Home and 
Health Depaitment with additional contributions from Cook UK Ltd 
(Hertfordshire, UK) , Biocompatibles Ltd, (Surrey UK) and Cordis, (Johnston & 
Johnston Medical Ltd, Berkshire, UK) .
5.3 Results
A total of 157 women were randomly assigned to the two study groups; 106 to the 
embolisation arm of the study and 51 to tire surgical aim of the study. Of those 
women who undeiwent surgery, 43 undeiwent hysterectomy and 8 underwent 
myomectomy (Figure 22).
Eight patients (5%) did not receive their allocated treatment (five in the 
embolisation group and three in the surgical group). There was one technical 
failure in the surgical aim with a myomectomy being converted to hysterectomy 
due to technical difficulties. All of the hysterectomies (43) and myomectomies (8) 
were performed through an abdominal incision. Three patients in the UAE aim 
had a technical failure due to difficulty identifying or catheterising one or both 
uterine arteries. The groups were well matched at baseline (Table 5).
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FIGURE 22
Trial profile at 12 months follow up
Allocated to UAE 
Received UAE 
Did not receive UAE
106
101 Allocated to surgery Received surgery 
Did not receive surgery 
" had UAE instead 
- Not treated
Allocation
Follow-up
Enrolment
Analysis
Randomised
157
546
patients screened
Lost to follow-upLost to follow-up
Analysed Analysed
Excluded
79 -  did not meet inclusion 
criteria 
192 -  declined participation 
123 -  had other reasons
389
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Table 5 Baseline chaincteristics of the patients
Characteristic 
Age (years)
Largest fibroid diameter (cm) 
Uterine volume (mis)
SF-36 Score
physical function 
role- physical 
bodily pain 
general health 
vitality
social function 
role- emotional 
mental health
EuroQoL Score
Main presenting symptom:
Number of patients (%) 
Bleeding 
Pain 
Pressure 
Other
Embolisation Surgery
(N=106) (N=51)
Mean S.D. Mean S.D. P value
43.6 5.5 43.3 7.1 0.77
7.5 3.0 8.5 3.9 0.12
579 447 701 627 0.23
82 19 77 20 0.16
51 41 45 42 0.35
52 22 50 22 0.60
61 19 60 23 0.92
41 22 42 23 0.93
63 27 58 30 0.34
60 43 57 43 0.76
63 18 63 22 0.91
70 16 63 20 0.04
102 50 0.92
56 (55) 29 (58)
19(19) 7 (14)
23 (23) 12 (24)
4(4) 2(4)
SF-36 and EuroQol scores range from 0 (worst possible health status) to 100 (best 
possible health status).
S.D. = standard deviation
All study paiticipants were pre-menopausal.
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Primary Outcome
The primaiy outcome measure (12 month SF-36 score) was available for 140 
(89%) of the 157 women. The results for the SF-36 and Euroqol at 1 and 12 
months ai'e given in Table 6. There was no statistically significant difference 
between UAE and surgery in any of the eight components of the SF-36 at 12 
months, although at one month, the embolisation group had significantly greater
-improvement in scores than the surgery group for physical function, social 
function and role-physical components.
Secondary Outcomes
Women in the surgical arm of the trial had a significantly higher pain score at 24 
hours (mean difference 1.6, 95% Cl 0.8 to 2.3, p <0.001). Symptom scores at one 
and 12 months after the procedure were significantly better in the surgical group.
The percentage of women prepared to recommend their treatment to a friend at 12 
months was high in both treatment groups (93% in the surgical group and 88% in 
the embolisation group) (p = 0.32) -  Table 7. The median hospital stay for UAE 
was significantly shorter than after surgery (1 day versus 5 days, p<0.001). The 
median time until patients could resume all recorded usual activities was 
significantly lower in the UAE group -  Table 8.
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Table 6
The effect of uterine artery embolisation and surgery on quality of life measures 
(SF-36 & EuroQol scores)
P
Embolisation Surgery Absolute Value
(n=106) (11=51) difference
mean S.D. mean S.D. (95% Cl)
SF-36 score
1 month
No.of patients 95 47
physical function 85 16 57 25 -26 (-32 to -20) <0.001
role- physical 37 44 11 24 -25 (-38 to -12) <0.001
bodily pain 50 22 44 24 -6 (“14 to 2) 0.16
general health 70 19 74 17 4 (-1 to 10) 0.13
vitality 47 22 42 24 -6 (-13 to 1) 0.11
social function 64 27 44 29 -19 (-28 to -9) <0.001
role- emotional 72 41 64 44 -7 (-22 to 7) 0.32
mental health 72 17 74 18 2 (-3 to 8) 0.39
12 months
No.of patients 95 47
physical function 92 14 89 20 0 (-6 to 5) 0.85
role- physical 76 40 81 34 7 (-7 to 20) 0.33
bodily pain 76 23 80 26 4 (-4 to 13) 0.28
general health 74 20 79 17 6 (0 to 12) 0.07
vitality 62 21 67 22 4 (-3 to 11) 0.26
social function 84 23 87 26 4 (-4 to 12) 0.35
role- emotional 81 35 87 30 7 (-4 to 18) 0.22
mental health 76 17 76 21 -1 (-7 to 5) 0.8
EuroQol at 1mill
No.of patients 92 47
Score 74 17 67 19 -4 (-9 to 2) 0.24
EuroQol at 12
mth
No.of patients 93 45
Score 82 16 83 14 4 (-2 to 9) 0.18
S.D. =  standaid deviation 
C l =  confidence interval
For tire differences in quality o f  life scores (SF 36 and EuroQol) between (lie surgical and embolisation arms, tiie analysis 
o f  covariance adjusted for baseline values. Thus, tlie differences between die two arras o f  die study are not the simple  
numerical differences. Negative values indicate higher scores in die embolisation mm  whilst positive values indicate higher 
scores in the surgical arm.
Scores range from 0 (worst possible healdi status) to 100 (best possible health status)
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Table 7
Post-embolisation and post-surgery symptom scores, pain scores and 
recommendation to a friend in the two treatment groups
Embolisation Surgery
N Mean SD N Mean SD
Dill
(E-S) 95% Cl P
24 hr pain
score 99 3 2.1 49 4.6 2.3 1.6 0.8-2.3 <0.001
(0 [no pain] to 10[severe pain])
Symptom
Score
1 month 98 1.5 2.4 48 2.8 2.6 1.3 G.4-2.2 0.004
12 months 95 3.6 2 45 4.3 1.7 0.7 0.1-1.4 0.03
(-5 [markedly worse] to +5 [markedly better])
Recommend to a friend
YES YES
Diff
(E-S)
1 month 74/97 76% 37/48 77% 1%
-14% to 
15% 0.92
12 months 84/95 88% 42/45 93% 5% -5 to 15% 0.32
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Table 8
Length of hospital stay and the time taken to achieve lifestyle milestones in days
I
S:
Embolisation Surgery
Diff in medians
(E-S)
Variable N Median QI Q3 N Median Ql Q3 95%  Cl
P
value
Hospital stay 100 1 1 2 49 5 3 6 3 to 4 <0.001
Made cup of 
tea 86 2 1 3 42 6 4 11 3 to 5 <0.001
Made meal 83 6 3 9 41 17 9.5 23 6 to 14 <0.001
Drove 66 8 5 10 30 34 27 43 22 to 30 <0.001
Return to work 68 20 14 30 31 62 39 90 28 to 53 <0.001
Sexual
intercourse 61 21 13 31 31 53 29 91 18 to 45 <0.001
Data are excluded tor patients who did not have a response to a category (e.g. non-drivers).
Minor Complications
Minor complications were reported by 36 women (34%) in the embolisation 
group and 10 (20%) in the surgical gi'oup (P-0.06) -  Table 9. Minor 
complications were most commonly associated with symptoms relating to the 
post-embolisation syndrome (52%) in the embolisation arm of the trial. In the 
surgical aim, minor complications were usually related to minor wound infections 
(25%). i:
' I
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#Major Adverse Events
There were 16 major adverse events (15%) in the embolisation group and 10 
(20%) in the surgical group during a median follow up of 32 months (interquartile 
range 23 -  41) ~ Table 9. When these events were categorized with respect to the 
timing of their occurrence (i.e. during the hospital stay, during the fh'st year of 
follow up or after the first year of follow up), 8 out of the 10 major adverse events 
in the surgical group occurred during the hospital stay whilst 15 out of the 16 
events in the embolisation group occurred after dischai'ge from hospital.
Treatment Failures
Twenty-one patients (20%) in the embolisation group required an additional 
invasive procedure (hysterectomy or repeated embolisation) for continued or 
recurrent symptoms. Ten of these procedures took place during the first 12 
months of follow up (2 of which were due to technical failures at the first attempt 
of embolisation) and 11 of these took place after the first yeai- of follow up. In the 
surgical group, there was one conversion of myomectomy to hysterectomy at the 
time of the primary procedure -  Table 9.
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Table 9
Minor Complications within first year
Major Adverse Events and Interventions for Treatment Failure -  occurring during 
median follow up of 32 mths
[for Major Adverse Events after 1 yeai% only tliose requiring hospitalization are reported.]
[P=0.047 for tlie com paiison between the embolisation group and tlie surgical group for M inor Complications] 
[P=0.22 for tlie comparison between the two study groups during the first year]
[the interquaitile range for Major Adverse Events and Reinteiventions for Treatment Failures was 23 -  41 mtlis]
Variable
Minor Complications 
at 1 yr
Patients reporting any minor 
complication -  no. (%)
Total number 
complications reported
Type o f  complication
MajorAdverse Events
Patients reporting any 
adverse event -  no. (%)
During hospital stay 
Total number
Tyjie o f event
During first year o f  follow  
up
Total number 
Tyjie o f event
A fter f irs t year o f  follow  up
Total number 
Type o f event
Embolisation Group (N=106) Surgical Group (N=51)
o f
36 (34)
50
postembolisation syndrome (26 patients) 
vaginal dischai'ge (9) 
sepsis (6) 
other (9)
Em bolisation G roup
16(15)
10 (20)
16
infection (4 patients) 
haemorrhage (3) 
other (9)
Surgical G roup
10 (20)
1 8
severe vasovagal event requiring atropine (1 operative haemorrhage (2  
patient) patients)
anaesthetic com plication (2)
wound infection (2)
wound haematoma (1 )
urinai-y retention (1)
12
breast cancer (2 patients) - both diagnosed 2  ratlis 
after treatment
pain and pelvic infection requiring readmission at 1 
and 4  weeks (2)
severe pain and fibroid expulsion at 3, 4 tuid 6 
weeks (3)
liaeniatometra at 6 montlis - not treated (1) 
pelvic abscess requiring hysterectomy at 10 mths 
(1 )
pei-sistent severe pain requiring hysterectomy at 8 
mths (1)
temporaiy am enonhoea for 5 and 9 nitlis (2)
3 0
persistent severe pain requiring hysterectomy at 15 
mdjs (1)
deatli from adrenal cancer (1) - diagnosis at 12 mtlis; 
deatli at 13 mtlis
severe pain and fibroid expulsion at 13 mtlis 
(1) 100
wound exploration under GA (1) 
wound infection at 3 weeks (1)
I
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T able 9 continued.
Interventions for 
Treatment Failure
Patients reporting any 
intervention - no. (%)
During hospital stay 
Total number
Type o f event
During first year o f  follow  
up
Total number 
Ty|)e o f  event
After f irs t year o f  follow  up 
Total number 
Type o f  event
Embolisation Group
21 (20)
Surgical Group
1 (2)
operative complication requiring 
technical failure o f  procedure requiring conveixion o f  m yom ectom y to
hysterectomy (2 patients) hysterectomy (1 patient)
hysterectom y (4 patients) 
repeated embolisation (4)
11
hysterectomy (8 patients) 
repeated em bolisation (3)
Other Outcomes
Up until September 2005, eight pregnancies have occurred in five women (seven 
in the embolisation group and one in the myomectomy group). Four of these 
pregnancies have miscarried, three have resulted in successful live births (two 
caesarean sections and one spontaneous vertex delivery) and one has culminated 
in an intrauterine death at 33 weeks gestation (no abnonnalities were found on 
post-moitem).
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5.4 Discussion
In this randomised trial compaiing UAE with standard surgical treatment for 
women with symptomatic fibroids, there were no significant differences between 
the tiial aims in teims of quality of life at 12 months, although in both arms, there 
were substantial improvements in each component of the SF-36 score relative to 
baseline. In contrast, the adverse event profiles were very different. Surgery was 
associated with the expected acute morbidity, but only one serious adverse event 
was recorded after the initial hospital stay. UAE was associated with a 
significantly faster recovery, including a shorter time to resumption of noimal 
activities.
Rates of minor complications or major adverse events did not differ significantly 
between the study groups although the nature and timing of these events vaiied 
between both aims of die trial. Major adverse events in the surgical group 
typically occuiTed during the hospital stay, whereas in the embolisation group, 
such events occurred more often than not, after discharge from hospital. Of note, 
three of the major adverse events in the embolisation group were cancers, all of 
which were highly unlikely to be related to treatment.
At one yeai', however, 10 of the 106 women in the embolisation arm requned a 
secondai’y procedure to treat persistent or recurrent symptoms. Beyond one year 
of follow up, 11 additional women were re-admitted to hospital for the same 
reasons. These findings are in keeping with data from previous uncontrolled 
published case series which indicate complications and treatment failures up to 48 
months after embolisation (Mai'ret et al. 2004a;Marret et al. 2005).
This tiial compai*ed two very different methods of treating women with 
symptomatic fibroids, namely surgery and UAE, where the pai'ticular surgical 
inteiwention and technical aspects of both procedures were not dictated by 
protocol. Thus both hysterectomy and myomectomy were included in the surgical
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aim although in fact only 8 women underwent myomectomy. The primaiy 
outcome measure of this trial, the SF 36, has been shown to be sensitive to 
changes in quality of life that result from successful treatment of menstmal
As mentioned previously, two other randomised controlled trials have been 
published, compaiing hysterectomy with UAE for the tieatment of symptomatic 
fibroids (Hehenkamp et al. 2005;Pinto et al. 2003). The first study used a rather 
controversial randomized consent methodology (Zelen 1979) where women
■•A
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symptoms (Jenkinson, Peto, & Coulter 1996). This is an important feature of the 
questionnaire, beaiing in mind the cyclical nature of symptoms experienced by 
many women with symptomatic fibroids. However, the SF 36 does not take 
specific fibroid-related symptoms into account, unlike the disease-specific UFS- 
QOL questionnaire (Spies et al. 2002a) which was not available at the 
commencement of the REST trial, hi this study, we did not collect data on 
objective menstmal blood loss (MBL) measurements. With only eight women in 
the surgieal ai*m of the trial undergoing myomectomy, it would not have been 
possible to present a meaningful comparison of MBL measurements between the 
surgical and UAE groups.
assigned to the hysterectomy aiiu of the study were neither informed of the study
■nor told about the alternative treatment of UAE. This paiticulai’ study was small, 
with recruitment of a total of 57 women. Length of hospital stay was the primaiy 
outcome measure and this was found to be shorter, in the embolisation arm of the 
study. Complication rates were similai’ in both study groups (Pinto et al, 2003).
The second trial enrolled 177 women, randomising them to either hysterectomy or 
UAE. Six weeks following treatment, women in the embolisation group were 
found to have a significantly shorter mean hospital stay, but there was also a 
higher minor complication rate and re-admission rate associated with this group 
(Hehenkamp et al. 2005).
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There aie a number of limitations to the REST trial which must be acknowledged.
The original target sample size of 200 was reduced to 150 owing to difficulties in 
recruitment. Whilst the 95% confidence intervals for the differences between the 
surgical and embolisation arms of the trial indicate that plausible results include as 
much as a 10-point difference between groups in some components of the SF 36, 
there is no suggestion of clinically important differences, hi addition, the 
recniitment of only a small number of women into the myomectomy sub-aim of 
the trial made it difficult to compaie this foim of uterine-sparing surgery to 
embolisation. However, it was not our aim to make meaningful compaiisons 
between UAE and myomectomy. The inclusion of myomectomy as a sub-arm of 
the trial was instead a pilot, to see if enough women could be randomised into a 
RCT in the future. Our experience with recmitment highlights how difficult it 
would be to compare UAE and myomectomy unless recmitment involved a very 
large population.
The use of time to resumption of usual activities as a secondary outcome measure 
can also be criticised as such an interval could be biased by the women’s 
expectations (with or without caregivers’ guidance) regarding time to recovery.
The REST trial shows very clearly that the choice between surgery and UAE for 
the treatment of symptomatic fibroids involves tradeoffs. The advantages of 
embolisation which include a significant reduction in length of hospital stay and 
24-hour pain levels as well as more rapid return to usual activities, must be 
weighed against the risk of treatment failure necessitating a second inteiwention 
and the rare, but nonetheless possible risk of major late adverse events. Longer- 
tenu follow up is still requned, with paiticular attention to the need for repeated 
intervention for treatment failure or late complications. This will allow women to 
be provided with better information to facilitate more informed decision making
:
prior to choosing treatment for then symptomatic fibroids.
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5.5 Conclusion
The results from the REST trial provide justification for the continued use of UAE 
in ti-eating women with symptomatic fibroids. Advantages and disadvantages 
compaied with surgery, however, ai’e now defined with more clarity. Further long 
term follow up of women undergoing UAE is required to evaluate the long term 
outcome and durability of the procedure.
105
Chapter 6
Late complication of uterine artery embolisation -
a case report
106
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îHM, a 51 year old para 3 + 0 presented to our gynaecology clinic with a pelvic 
mass extending to her umbilicus. She gave a three month history of lower 
abdominal discomfort associated with both backache and fatigue. Her periods 
were irregular, but normal in flow. HM had just stopped a sequential combined 
preparation of honnone replacement therapy, commenced five years earlier, for 
peri-menopausal symptoms. Abdominal examination revealed a central non- 
tender pelvic mass equivalent to a 16 week sized pregnant utems; bimanual 
vaginal examination findings were consistent with the latter and confirmed that 
the mass was mobile. Subsequent pelvic ultiasound revealed a 14 x 12 centimetre 
(cm) solid mass within the fundus of the utems, in keeping with a uterine fibroid.
All other uterine findings were noiinal.
After a long discussion regarding the various ti'eatment options for symptomatic
fibroids, HM agreed to consent to entry into the REST trial. She was subsequently 
randomised into the embolisation aim of the trial and after review once again by a 
gynaecologist and thereafter, by an interventional radiologist, she underwent MRI
■v-
of her pelvis as per protocol of the trial. This demonstrated a heterogenous uterine 
intramural mass 10.8 x 9.4 x 8 .8cm consistent in appeai*ance with a fibroid, and an 
overall uterine volume of 447cc. Gadolinium enhancement was not peiformed as 
HM was recmited in the eaiiy stages of the tiial when this was not part of the 
standai'd protocol. White cell count, CRP and Hb levels were all within normal 
reference ranges prior to treatment. Outwith the REST trial, HM agreed to 
objective menstmal blood loss assessment using the alkaline haematin method.
Her blood loss from one menses was calculated to be 16mls.
UAE was then peiformed using the standai’d technique described in chapter 1, 
section 1.8, page 36). Post-procedure, HM experienced only mild lower 
abdominal cramps. Pain was managed using a combination of intravenous opiates
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and oral non-steroidal anti inflammatory drugs over the first twenty four hours
■and she was discharged from hospital the following day.
One month following treatment, HM was reviewed by a reseai’ch nurse as per the 
REST trial follow-up protocol. Whilst she felt that her symptoms had slightly 
improved, she did admit to an increase in menstrual flow since ti'eatment, in 
association with moderate dysmenorrhoea and lower backache.
Thi'ee months post-UAE, HM reported further improvement of symptoms to her
gynaecologist. In paiticulai', she felt that her abdominal mass had decreased in 
size, resulting in less abdominal and pelvic discomfort. She also remai'ked at this 
point that she would recoimnend UAE to other women.
At her six month review, HM continued to report improvement in abdomino- 
pel vie symptoms. However, she also reported fatigue, dysmenoii'hoea and an 
increase in menstrual flow associated with the passage of clots, flooding and the 
requirement of additional sanitaiy protection. At this stage, the reseai'ch nurse 
recomiuended the use of an oral anti-fibrinolytic, tranexamic acid, in order to 
reduce menstmal blood loss. Shortly after review, a six month post-treatment MRI 
was peiformed as per trial protocol. Whilst the fibroid mass was found to have 
decreased in size (8.9 x 6.0 x 7.5cms), it was noted to be suiTOunded by some 
fluid. Thus, combining fibroid and fluid volume demonstrated that uterine volume 
had decreased to 424cc, a very minimal overall reduction, when compared to pre­
treatment values.
Eleven months after ti'eatment, HM presented to her general practitioner with left 
lower abdominal pain and distension during the fii'st few days of her cycle. After 
clinical examination, subacute bowel obshucflon was suspected and thus HM was 
referred and admitted to hospital as an emergency. On admission, HM also 
presented with nausea and vomiting, subcostal pain radiating to both shoulder tips 
and heavy menstmal bleeding. On examination, she had a pyrexia of 38.5^ C and
Ï
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a soft, generally tender abdomen associated with a pelvic mass extending to her 
umbilicus. WCC was minimally elevated (13.8 x 10'3 L), CRP was increased at
145 mg/dL and Hb was within the normal reference range. Pelvic ultrasound 
peifoiined at this time revealed a uterine cavity thought to contain an 8.0 x 7.4 x 
7.7cms blood clot. Blood cultures were negative and after a single dose of 
intravenous antibiotics (augmentin), HM was apyrexial. hiti'amusculai' opiate 
analgesia was administered and HM was discharged form hospital 3 days later 
when her abdominal pain resolved, with a combination of oral antibiotics and 
analgesia.
Unfortunately, HM’s symptoms persisted over the next few weeks and after 
discussion with her consultant gynaecologist, the decision was made to proceed 
with total abdominal hysterectomy and bilateral salpingoophorectomy (TAH and 
BSO); this was scheduled for six weeks later.
Another MRI was performed in the interim, at twelve months post-UAE. The 
fibroid was measured to be lOcms in diameter and the uterine volume was 500cc, 
More specifically, the fibroid mass was noted to have a cential oval solid 
component measuring 8.0 x 5.0 x S.Ocms within a lai’ger outer cystic component 
measuring 10 x 10 x lOcms. These appearances were thought to be to be
suggestive of the fibroid undergoing partial cystic necrosis, leaving a residual
central component. Gadolinium enhancement was performed with this MRI, to
assess uterine vascularity. This demonstrated poor enhancement of the remaining
solid component, suggesting that the fibroid was relatively hypovascular'. At this
point, HM, influenced by a combination of her MRI findings and improvement of
her clinical symptoms, decided to cancel her hysterectomy. Whilst she did have
concerns regarding deterioration of her clinical symptoms, she was keen to avoid
ruajor surgery and instead, have her symptoms monitored over the course of the
next few weeks. Objective menstnral blood loss measurement performed at twelve
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months revealed a blood loss of 161mls, a volume much in excess of HM’s pre- 
UAE measurement.
One month later (13 months post-UAE), HM was admitted to hospital as an 
emergency with lower abdominal pain, backache and heavy vaginal bleeding. A
3
borderline pyrexia was noted. Pelvic ultrasound confhmed tire presence of an 
echogenic fluid collection ai'ound the fibroid. HM was still keen to avoid surgery
at this point and thus the decision was made to perform ultrasound-guided
aspiration of peri-fibroid fluid; this yielded 80 mis of thick green fluid. 
Microscopy of the latter revealed a moderate amount of white blood cells in
HM was dischai'ged on the following day and was requested to complete a course 
of oral antibiotics in the fonn of augmentin and metronidazole. She was also 
given oral antiemetics and analgesia to self-administer as required.
Two weeks later, HM was reviewed by her consultant gynaecologist once again. 
Her symptoms of gmmbling lower abdominal and pelvic pain persisted and she 
now was experiencing heavy vaginal bleeding. Taking her symptoms and imaging 
into consideration, she decided to go ahead with a hysterectomy in the near future. 
Surgery was scheduled for the following month and just prior to her operation, 
HM underwent a further pelvic ultrasound. This demonstrated a posterior uterine 
wall cystic mass ~ 13cms diameter. This was associated with free fluid in the 
pouch of Douglas. Within the cystic mass, locules were seen; these were thought 
to possibly represent an abscess.
Surgery in the form of TAH and BSO went ahead as planned, 15 months post-
embolisation, Intraoperatively, a laige fibroid uterus extending to the level of the
umbilicus was noted. This was associated with dense bowel and omental
adhesions in the pouch of Douglas which required mobilisation in order to
facilitate hysterectomy. A myomectomy screw was inserted into the uterus for
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association with scanty gram negative cocci. Culture, however, yielded no growth. I
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Ielevation. This caused a purulent exudate to ooze from within the uterine cavity (Figure 23). Both tubes and ovaiies were nonnal. Blood loss during surgery was 
estimated at 400mls. A diain was inserted into the abdominal cavity at the end of 
the procedure. Intraoperative and post-operative intravenous antibiotics were 
administered (metronidazole and gentamicin) owing to the presence of pus. Pre­
operative Hb was 10.8 g/dL. This dropped to 9.3 g/dL iimnediately after surgery. 
On day one following hysterectomy, HM collapsed in the shower and was noted 
to have 400ml of blood in her pelvic drain. Hb was noted to have dropped further, 
to 6.3 g/dL. Two units of packed red cells were subsequently transfused which 
increased the Hb level to 7.7 g/dL. Oral iron supplements were administered, 
thereafter. HM subsequently made an excellent post-operative recovery and was 
discharged on day 6 post-surgery, on oral analgesia and honnone replacement 
therapy in the form of oral oestrogen.
Following hysterectomy, the fresh uterine specimen was opened; this revealed a 
lai'ge necrotic fibroid within the uterine cavity (Figure 24). Pathological analysis 
of the specimen revealed a lai'ge discoloured fibroid or leiomyoma, 10 x 7 x 7cms 
in size. This was almost 100% infai'cted, presumably as a result of embolisation. 
The adjacent suiTOunding myometi'ial tissue appeared necrotic on macroscopic 
examination and microscopy showed extensive ai’eas of acute suppuration with 
abscess formation accompanied by neutrophil polymorphs and histiocytes. There 
were also foci of tissue necrosis. Endometrium was proliferative and other-wise, 
pathology was unremar'kable. Uterine swabs taken at the time of surgery were 
negative and revealed only scanty white blood cells.
HM was reviewed 6 weeks after her surgery and was found to be clinically well 
and asymptomatic. Despite her post-embolisation complications, she stated that 
she would still recommend UAE to women who have symptomatic fibroids.
Figure 23
Gross specimen of uterus demonstrating ooze of purulent exudate from site of 
myomectomy screw insertion
Figure 24
Large necrotic fibroid within uterine cavity
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Discussion
Uterine artery embolisation appears to be comparable to hysterectomy in terms of 
safety, efficacy and patient satisfaction. However, as previous studies have
demonstrated, the short hospital time and recovery period associated with the 
procedure must be balanced against the risk of complications and need for re­
hospitalization and / or further treatment, in a minority of patients. We ai'e aware 
of the minor complications associated with UAE such as pelvic pain, the post- 
embolisation syndrome and persistent vaginal discharge. Most of these problems 
are self-limiting and can be managed with conservative measures. Major 
complications such as pelvic sepsis necessitating hysterectomy and death have 
been reported, but these tend to occur rar'ely, within the fhst few weeks or months 
of ti'eatment.
The case of HM is unusual in terms of the timing of presentation of symptoms 
after UAE and their course prior to hysterectomy. Late complications after UAE 
appear* to be reported very rarely in the literature. M anet et al have published a 
case involving a woman who underwent successful UAE for a 13 x 12cm intra­
mural fibroid (Marret et al. 2004a). Fibroid reduction was achieved and symptoms 
were successfully controlled until 44 months post-ti'eatment, when the woman 
developed a persistent pumlent vaginal dischai'ge. Subsequent hysteroscopy 
revealed a 7cm posterior wall necrotic fibroid, partially submucosal and 
protmding into the uterine cavity. The woman declined hysterectomy and went on 
to spontaneously expel her fibroid per vaginum via the cervix, 6 months later, 
with no ill effects thereafter.
HM initially experienced improvement of symptoms at three months post-UAE. 
Six months after embolisation, however, she experienced deterioration in 
symptoms, with episodes of paitial remission followed by further deterioration up 
to 13 months after ti'eatment. Perhaps a number of women with her symptoms of
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abdominal and pelvic pain associated with increasingly heavy periods would have 
opted for hysterectomy at an earlier stage. Certainly, HM’s symptoms which 
waiTanted emergency admissions 11 and 13 months post-UAE, in combination 
with imaging peiformed on these separate occasions, hinted at an infective cause 
for her ongoing problems. It is nonetheless unusual for a patient to present with 
infective complications following UAE after such a lapse of time. This case report 
and the one published by Marret et al, emphasise the need for long term follow up 
of women undergoing embolisation. In addition, clinicians and patients should be 
made aware of the potential for delayed presentation of major complications after 
treatment. Our case also highlights the need for us to have a better understanding 
of the predictive factors (e.g. fibroid size) for the success of UAE for symptomatic 
fibroids.
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Chapter 7A
Vasculature of human myometrium and 
leiomyomata
-S
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7A.1 Introduction ■'S
The human uterine vasculature is highly structured, exhibiting circumferential and 
radial branching. This stmctured ai'chitecture appeal's to be absent in uterine 
fibroids. Angiography used to study normal uterine vascular morphology has also
■
been used to analyse fibroid vasculature and this shows substantial differences 
between normal and diseased tissue (Farrer-Brown, Beiby and Rowles
1970a;FaiTer-Brown, Beilby & Tai'bit 197Ob;Farrer-Brown, Beilby & Taibit
197Oc;FaiTer-Bi'own, Beilby & Taibit 1970d). Morphometric analysis in tissue
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sections suggest that fibroids lack the well developed vascular pattern seen in 
nonnal myometrium (Casey, Rogers, & Vollenhoven 2000;Gai'gett et al. 
2002;Hague et al. 2000;Poncelet et al. 2002;Weston et al. 2003). Although 
existing evidence indicates a vasculai* gradient within the myometrium, this has 
not been quantified stereologically. In addition, the apparent lack of a stmctured 
vascular gradient within fibroids has not been described in compaiison with 
normal uterine tissue.
Based on our previous knowledge of the anatomical distribution of uterine 
vessels, it is postulated fiistly, that a spatial gradient of vessel wall density and 
vessel size exists within the normal myometrium and secondly, that there is a 
precise relationship between vessel calibre and tortuosity. Finally, we postulate 
that this difference between inner and outer myometrium is dismpted in fibroid 
growth. It is hoped that the compai'ison between vessel musculai'ization in fibroid
and normal myométrial tissue may detemnine potential reasons for fibroid growth
-and provide some explanation for the anatomical rationale for uterine aitery 
embolisation.
,1j;
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7A.2 Materials and methods 
7A.2.1 Tissue specimens
Archival samples of 12 non-fibroid and 19 fibroid uteri were obtained from 
Pathology Depaitments of North Glasgow Acute NHS Trust Hospitals for
3
analysis. Eleven biopsies were also obtained on a prospective basis (eight fibroid 
and three non-fibroid) from women undergoing hysterectomy for menorrhagia. 
Negative controls included slides incubated without the primaiy antibody and 
sections with a mouse monoclonal antibody against immumoglobulin G (IgG), 
Placental tissue was used as a positive control for the primaiy antibody (mouse 
monoclonal antibody) used. The mean ages of patients in the non-fibroid and 
fibroid groups were 39 yeai's (range 29-48) and 41.25 years (range 33-54), 
respectively.
Five of the patients in the fibroid group had undergone previous treatment with a 
gonadotrophin-releasing hormone analogue, but all had at least a 3-month dmg- 
free period prior to hysterectomy. No hormonal treatment had been administered
:to any of tire women without fibroids before sm-gery. Of the 15 non-fibroid uteri, 
the endometrium was proliferative, secretory and menstrual in 5, 9 and one 
specimen, respectively. In the fibroid group, endometrium was secretory, 
proliferative, inactive and severely autolysed in 15, 8 , 3 and one case, 
respectively. Thi'ee specimens in each group were found to have other pathology; 
specifically, four cases of endometriosis, one case of adenomyosis and one 
endometrial polyp. None of these pathologies had any effect on the acquisition of 
numerical data. Two fibroid specimens were excluded before analysis owing to 
distortion secondary to necrobiosis, making it impossible to analyse the tissue.
The mean cross-sectional diameter of fibroid analysed was 25.25mm (range 5- 
40imn). Six uteri contained a single fibroid whilst 21 uteri contained multiple
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lesions. Of the fibroids that were not analysed, the lai’gest was 200mm in 
diameter. Twenty two of the 27 fibroid specimens contained intramural fibroids. 
The remainder were submucosal in origin.
Ethics approval and patient consent were obtained for this study.
map image were then matched with the microscopic field of view (2x objective,
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7A.2.2 Stereological analysis of the myométrial vascular gradient
Fonnaldehyde fixed and wax embedded tissue sections (5pm) orientated along the 
endometrial-serosal axis were used for analysis. The vascular endothelium was 
visualised by immunocytochemical detection of CD-31 (Dako) after antigen 
retrieval. Endogenous peroxidase activity was inactivated by immersing the slides 
in 0.5% hydrogen peroxide in methanol. The sections were then microwaved in 
0.01 mol/1 citrate buffer pH 6 for 8 minutes. Antibody-binding sites were blocked 
with 20% horse senrm in phosphate buffer solution (PBS) for 30 minutes at room 
temperature. Antibody binding was detected with an avidin-biotin-peroxidase kit 
(Vector laboratories, Peterborough, UK) and diaminobenzine. The sections were 
then counterstained with haematoxylin. The distribution of vasculai' smooth 
muscle was estimated using the pattern of haematoxylin stained nuclei, as it is 
difficult to distinguish antigenically between myométrial smooth muscle and 
vascular' smooth muscle in wax embedded tissue sections.
Images of whole sections were obtained by transmitted light scanning with a 
35mm film scanner (Nikon Coolscan III). A uniform 3x3mm sampling grid, 
randomised by starting point and position, was applied to these map images with 
the grid function of Adobe Photoshop (Russ and Dehoff, 2000). The tissue was 
thus divided into six zones, zone 1 being nearest to the myometrial-serosal 
boundary (outer myometrium) and zone 6 being nearest to the endometrial- 
myometrial boundary (inner myometrium) -  Figure 25A. Sampling points on the
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Olympus BX-50 microscope). Digital images of microscope fields centred on the 
grid points were captured with a 40x objective using a 3-CCD colour video 
camera (KY55, JVC). Stereological analysis of the sample fields was then carried 
out using the grid function of an image analysis programme (Image Pro Plus 4.5, 
Media Cybernetics). A 48 point orthogonal grid with a spacing of 100x100 pixels 
was applied in order to make estimates of muscularized vessel wall and lumen, 
and capillaiies within each tissue section (fractional volume estimates). A total of 
720 fields were counted in nonnal myométrial sections and 1248 fields in fibroid 
specimens (Table 10).
Table 10
The number of fields used within each zone for the stereological analysis of vessel 
volume fraction
Zone Number of fields analysed
Normal Myometrium Fibroid
Perifibroid Fibroid Myometrium
Around
Fibroid
1 124 7 110 87
2 120 29 102 99
3 136 44 86 82
4 118 50 94 122
5 124 42 72 110
6 99 31 76 55
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Figure 25
Diagrammatic representation of the tissue cross sections being analysed.
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(A) Stereological analysis of tissue in zones applied to two different 
fibroids, varying in size and position along the endometrial-serosal axis.
(B) Illustrations of the measurements undertaken for stereological analysis of vessel volume 
fraction (left) and morphometric analysis (right). Volume fraction was determined by counting the 
number of grid points intersecting with each phase of interest. Simple linear measmements of 
vessel cross section were made for morphometric analysis.
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Unlike stereological analysis, morphometric analysis enables the chai*acteristics of
7A.2.3 Morphometric analysis of vessel size
%
a single vessel to be described. Morphometric analysis was undertaken to 
deteimine whether or not there was a gradient in vessel size within the 
myometrium. Cross-sectional area (luminal area) and maximum and minimum 
diameters of vessel lumen were measured on 960 and 315 vessel cross sections in 
normal myometrium and fibroid tissue, respectively.
In order to study the spatial gradient of vessel size, sampling lines orientated 
along the endometrial-serosal axis were generated on the scanned map images. 
Sampling points spaced at the equivalent of 1mm intervals on the tissue were then 
used to locate microscope fields. Each of these sampling points was viewed using 
a 40x objective, and a digital image of the vessel neai’est the sampling point was 
captured. Where the entire vessel could not be visualised in one image, the slide 
was rotated to capture it. Care was taken to ensure the same vessel was not re­
sampled. Manual image analysis tools (Image Pro Plus 4.5, Media Cybernetics) 
were used to make measurements of cross-sectional luminal ai'ea by manually 
outlining with the mouse. The maximum and minimum diameters, represented by 
Feret diameter (or calliper widtli), were computed automatically by the 
programme from the outline (Figure 25B).
Orientation of the muscularized vessel cross-sections was also measured 
manually, from the low magnification (2x) images, using a protractor. Profiles 
with a circulai’ or neai’-circular plane of section were excluded. Only fibroid 
specimens in which the endometrium was clearly visualised and orientation was 
clear were used for this analysis.
■
In order to represent the large vaiiation in vessel size, histograms with
discontinuous axes were created to encompass the range of values. Composite
scattergrams were required to show the spatial distribution of vessel size within
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fibroid containing specimens. This was due to the fact that the specimens varied in 
width and the fibroids varied in cross-sectional diameter and position within the 
muscle. The data were broken into 4 subsets and aligned on the histogiam using 4 
spatial boundai'ies (endometrial- myometi’ial boundai’y, edge of fibroid neai*est 
endometrium, edge of fibroid nearest serosa and the myométrial-serosal 
boundary). Data ai*e presented as mean +/- the standard error of the mean 
(S.E.M.).
7A.2.4 Image analysis of vascular tortuosity
Initial attempts to produce high resolution 3-dimensional images of the uterine 
vasculature on isolated hysterectomy specimens with a small bore 7-Tesla 
magnetic resonance imager produced images that were not suitable for analysis. 
Although the tortuosity of the larger vessels could be dkectly observed, ai’tefacts 
within the prepaiation produced an artificially dilated appearance of the lumen. 
However, as the detection of small vessels was limited by resolution, manual 
image analysis was caiiied out on the published uterine ai'teriograms of Farrer- 
Brown et al (1970a). The projections of the vessels seen in these images were 
scanned at 600 dots per inch (dpi), and lineai' measurements were then made on 
38 aibitraiy vessel segments using the measure tool of Adobe Photoshop. Only 
tortuous vessels segments were used, as straight portions in the plane of view 
would have had zero values for the pai'ameters measured. Luminal diameter was 
measured at the beginning and end of a segment and at each projected turning 
point. In order that tortuosity could be measured at a consistent luminal diameter, 
measurements were restiicted to segments where there was less than 10% end-to- 
end vaiiation in vessel width. Projected amplitude was measured orthogonally 
from an aibitrary line connecting both ends of the segment. Wavelength was
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calculated as the number of bending cycles divided by the projected straight linear 
distance (Figure 26).
Figure 26 Diagrammatic representation of an aiterially filled vessel 
segment from Farrer-Brown et al. (1970d).
Manual analysis of the projected image was undertaken with the linear measurement tool. Luminal 
width (W) was measured at turning points and at the beginning and end of each measured segment. 
Tortuosity of the vessels was assessed by measuring wavelength (L) and amplitude (A). 2D eiTor 
bars are included because of the variation in assessment of luminal diameter over short vessel 
segments. The eiror bars represent the SEM,
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7A.3 Results
Immunolocalisation of CD-31 allowed identification of blood vessels within 
myometrium and fibroids (Figure 27A-D).
Figure 27
Immunocytochemical localization of vascular endothelium 
with anti-CD-31 antibodies.
(A) Normal myométrial tissue showing a range of muscularized vessels. (B) Fibroid tissue with an 
absence of muscularized vessels and a lower density of vascularization. (C) Lower magnification 
images showing fibroid (F) and myométrial tissue (M). Large muscularized vessels are present 
close to the fibroid boundary. (D) Perifibroid tissue containing large thin-walled circumferential 
vessels, fibroid (F) and myometrium (M). Note the lower area fraction of vessel in the fibroid 
shown in D compared with that shown in C. Analysis was carried out at higher objective lens 
magnifications than illustrated. Scale bars = 100 pm.
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Large thick-walled vessels were present within the myometrium but were not 
detected in small fibroids. The perifibroid tissue, near the fibroid, contained large
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thin walled, circumferential vessels and was distinct from both normal and fibroid 
tissue in this respect (Fig.27D), Stereological analysis of normal myometrium 
specimens (n=15) confirmed the existence of an anatomical gradient of vessel 
musculaiity within the myométrial vascular system (Figure 28). This gradient is 
unaffected by the stage of the menstmal cycle.
A two-way analysis of vaiiance demonstrated a significant vaiiation along the 
endometrial-serosal axis (P=0.04) and no effect of menstmal cycle stage (P=0.71). 
There is a greater volume fraction of vessel wall in the outer myometrium than in 
the inner myometiium (Figure 28A). This spatial gradient could not be detected 
within fibroids (n=27), which had a negligible volume fraction of muscularized 
vessel wall, or within the perifibroid tissue. Myométrial tissue outside the 
perifibroid zone of lai'ge thin-walled vessels also appealed affected by the 
presence of the fibroid since the gradient of average vessel fraction and the ratio 
of vessel lumen to wall seen in normal tissue was dismpted (Figure 28A and B). 
The ratio of vessel lumen to wall had a similai' distribution to vessel volume 
fraction, confmning that vessels were less musculaiized within the inner 
myometrium (Figure 28B, Table 11). The lumen to wall ratio could not be 
reliably calculated in fibroid tissue as musculai'ized vessels were observed very 
infrequently (Figure 28B).
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Figure 28 Stereological analysis of vessel wall distribution within the 
musculaiized vessels. (A) There is a continuous decrease in the vessel wall fraction from the 
serosa to the endometrium in normal tissue (n -  15) (continuous line connecting diamonds). By 
contrast, the fibroid has very little or no vessel wall (n = 27) (dotted line connecting triangles). 
Large thin-walled vessels are seen in the perifibroid area (dots and dashes connecting crosses). The 
perifibroid region has a consistently higher volume fraction throughout the width of the 
myometiium. The myometrium in fibroid specimens outwith the area of large vessels does not 
demonstrate a continuous trend in vessel size (dashes connecting boxes). (B) The ratio of vessel 
walhlumen (continuous Line connecting diamonds) shows a similar continuous trend as average 
vessel fraction. Tissues out with the fibroid do not show this continuous trend (dashes connecting 
boxes and dots and dashes connecting triangles). EiTor bars represent the standai'd eiTor of 
themean (SEM).
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Table 11
Average musculaiized vessel volume fraction comparison by endometrial stage
Average musculaiized vessel volume fraction compaiison by endometrial stage
Zone Proliferative Secretory
1 0.18 0.175
2 0.16 0.17
3 0.1 0.11
4 0.06 0.06
5 0.05 0.055
6 0.05 0.05
I
Phase of the menstmal cycle did not influence myométrial 
vascularity as judged by the musculaiized vessel volume fraction within 
nonfibroid tissue
Analysis of the volume fraction of capillary walls within the normal tissue 
suggested that there was no spatial difference in microvascularity across the 
myometrium (Figure 29). The same was tiue of fibroids. It was also apparent that 
the fibroids had a smaller fraction of capillaries as deteiinined by the capillary 
wall fraction (Figure 29).
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Figure 29
Stereological analysis of the capillary wall fraction -  shows no obvious spatial gradients, 
within normal tissue {n = 15) (continuous line connecting diamonds), witliin the fibroid {n = 27) 
(dotted lines connecting triangles) or in the tissue surrounding the large perihbroid vessels (dashes 
connecting squares).
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Moiphometric analysis demonsti'ated a difference in the distribution of vessel size 
that was consistent with the stereological data. The inner myometrium close to the 
endometrium contained vessels of small minimum cross-sectional diameter. With 
increasing distance from the endometrial-myometrial boundary, vessels with 
larger cross-sectional areas were also present (Figure 30A). There appeared to be 
a bimodal distribution of vessel cross-sectional aiea within the inner and outer 
myometrium. The smaller peak coixesponded to capillaries and the larger one, to 
musculaiized vessels. The lai'ger musculaiized second peak of the distribution was 
more obvious in the outer myometrium where lai’ger vessels were present (Figure 
30B). Vessels within fibroids were smaller and did not have a bimodal 
distribution since the larger musculaiized vessels were almost totally absent. 
Analysis of the minimum vessel cross-sectional diameter demonsti'ated that the
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distlibution of vessel size within the fibroid had a smaller modal value and a very 
narrow range (Figure 30C), indicating that the capillaries within the fibroid were 
smaller and more uniform in size than capillaries in the normal myometrium. 
Within the perifibroid tissue there were vessels of lai'ge cross-sectional aiea 
(Figure 30D).
129
!■
:-V
■|
Figure 30
Moiphometiic analysis of cross-sectional vessel area and minimum diameter.
(A) The scattergram of minimum cross-sectional vessel diameter in normal tissue demonstrates 
that there is a change in the distribution in vascular' size between inner and outer myometrium. 
Each point represents one vessel cross section, whereas each symbol type conesponds to one 
patient. (B and C) Discontinuous histograms of cross-sectional vessel area (B) and minimum 
vessel diameter (C) in inner and outer myometrium and in fibroid tissue. Hatched bars show the 
outer half of the normal myometrium, open bars represent inner myometrium and black bars show 
fibroid tissue. A bimodal distribution of cross-sectional vessel area is particularly obvious in the 
outer myometrium (B). The vessels within the fibroid have a smaller modal value and range than 
the normal myometrium (C). (D) Composite scatterplot of cross-sectional vessel area in fibroid 
specimens demonstrating large vessels in the perifibroid region. The scale of the horizontal axis is 
split and aligned by four spatial boundaries (endometrial-myometrial boundary, fibroid edge 
nearest endometiium, fibroid edge nearest serosa and serosal boundary). Each point represents one 
vessel cross section, whereas each symbol represents one patient.
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There was no obvious orientation of vessel cross-sections within the normal 
myometrium (Figure 31 A). The ckcumferential perifibroid vessels appeared 
concave in cross-section. A line joining the end points of the cross-sections tended 
to be orientated peipendicularly to the endometrial-serosal axis (Figure 3IB). 
This orientation resulted from the plane of section.
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Figure 31
Composite scatterplots of vessel cross-section orientation.
The scale of the horizontal axis is split and aligned by four spatial boundaries (endometrial- 
myometrial boundary, fibroid edge nearest endometiium, fibroid edge nearest serosa and serosal 
boundary). (A) There is a lack of vessel orientation along the endometrial-serosal axis in normal 
myometrium. (B) Within fibroid-containing specimens, the perifibroid region has large thin-walled 
circumferential vessels. The ends of their concave cross sections have a similar* position along the 
endometrial-serosal axis, which produces a clustering in the orientation scattergram.
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Manual analysis of the arterial angiographic projection images of Fairer-Brown 
and colleagues (1970a) demonstrated a lineai* relationship between luminal size 
and tortuosity, Lai'ger vessels exhibited a higher amplitude and lower frequency of 
bending than smaller vessels (Figure 32).
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Figure 32
Manual image analysis of the angiograms of Fairer-Brown t aL shows a cleai* correlation 
between (A) luminal width and amplitude, (B) luminal width and wavelength and thus (C) a co- 
correlation between amplitude and wavelength.
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7A.4 Discussion
Stereological and morphometric analysis in the present study demonstrated a 
decreasing gradient of vascular smooth muscle abundance from the outer to inner 
myometrium, but a uniform capillary distribution. These observations were 
complemented by our analysis of the uterine aiteriograms previously published by
■ii
Farrer-Brown et al. In conti'ast, an absence of vascular smooth muscle and large 
diameter vessels was observed in small fibroids. These results supplement 
existing research in the field, allowing clarification of the precise anatomy of 
uterine and fibroid vasculature. They also provide further insight into fibroid 
vascular- development and permit speculation regarding the anatomical rationale 
for uterine ai'tery embolisation. Furthermore, this study uses robust 
methodological techniques to draw a comparison between fibroid vasculature and 
tliat of normal myometr ium.
The present findings agree with Casey et al. (Casey, Rogers, & Vollenhoven 
2000) who selected areas of high and low vascular density and used image 
analysis to conclude that small fibroids have a smaller vascular diameter than 
normal myometrium. However, the measurement of vascular- luminal diameter in 
Casey et al. was dependent on the endothelial mar-ker used. Paradoxically, CD-31 
did not highlight any differences in luminal diameter of vessels within fibroids. 
The present study also varied metliodologically from that of Casey et al. because 
we made no attempt to select ar'eas based on vascular- density. A deliberate 
selection of vessel types could exaggerate the difference between normal tissue 
and fibroids since it is not possible to select large vessels within fibroids.
Other studies of fibroid vasculature have used the ‘hot spot’ counting method, 
which en-oneously counts vessel profiles and biases the analysis in favour of 
highly vascularized areas (Poncelet et al., 2002). Although there is no quantitative 
justification for the use of a non-randomized sampling design as practiced by the
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‘hot spot’ method, it might be that tumour growth and the risk of dissemination is 
related to peaks of angiogenesis in particular' types of tumours. Corxelations 
between ‘hot spot’ counts and patient suiwival in malignant conditions are likely 
to be numerically associated as only the upper tail of the distribution is being 
selected for counting (Tas et al., 2000; Skoldenberg et al., 2001). hr the case of 
non-rnalignant solid tumours such as fibroids, ‘hot spots’ of vascularization could 
be related to local growth. ‘Hot spot’ counting is intrinsically unsuited to the 
measurement of average values, contravenes modern design-based sampling 
approaches and should therefore not have a place in the assessment of normal 
tissue (Howard & Reed 1998).
Another important methodological consideration is the nature of the counting 
(stereological) probes used in vascular* analysis. Some authors now seem to use 
the Chalkley counting grid in a way different to that originally contemplated by its 
designer (Hague et al. 2000). Chalkley originally designed the probe to be applied 
in a random position and orientation so that unbiased estimates could be produced 
(Chalkley 1943). Recent studies of the fibroid vasculature have deviated from the 
principle of random grid orientation. Use of the Chalkley method is also non- 
standard when applied to ‘hot spots’.
The decreasing gradient of vascular smooth muscle abundance within the 
myometrium (from outer to inner aspects) demonstrated in the current study is 
consistent with previous angiographic studies outlining the distribution of arteries 
and veins within the myometrium (Farrer-Brown, Beilby and Tartit 1970b; 
Faner-Brown, Beilby and Tarbit 1970c). The anatomical explanation for these 
findings is that tire lar ger arteries and veins present in the serosal aspect of the 
myometrium then branch and taper to form narxower radial vessels penetrating 
deep into the myometrium (Ramsey 1994). By contrast, there was a uniform 
distribution of capillaries throughout the myometrium as determined by the tissue
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fraction occupied by capillar y wall. The even density of capillary wall suggests 
that there is uniformity of perfusion in inner and outer myometrium.
Orientation of vessel cross sections would be expected to be influenced by the 
tortuosity of vessels rirnning radially within the myometrium. The present
findings suggest that tortuosity does indeed randomize these orientations. 
Paradoxically, the orientation in perifibroid tissue deviates from the random 
pattern seen in healthy tissue. It might have been expected drat the course of radial 
vessels would be distorted by the presence of small fibroids, and they would thus 
appear' to be orientated along the endometrial-serosal axis as they deviated around 
the fibroid. However, our findings show that the concave vertically sampled 
vessel cross sections were orientated in a plane par'allel to the endometrial- 
myometrial junction. This illustrates then circumferential nature around the 
fibroid rather than orientation.
Analysis of the published ar'terial angiographs of Faner- Brown et al (Far'rer- 
Brown, Beilby and Tarbit 1970b) demonstrated a linear’ relationship between 
luminal width and measures of arterial tortuosity, providing a link between vessel 
size and the pattern of bending. It would seem reasonable to assume that tortuosity 
is related to wall thickness and consequently physical stiffness of the vessel. 
However, even highly flexible lar'ge diameter str-uctures could not bend to the 
same extent as small diameter vessels purely for reasons of size. Arteries withm 
the myometrium assume a tortuous course, because the length of the vessel is 
greater than that of the equivalent linear' dimensions of the surxounding tissue 
(Jackson, Gotlieb, & Langille 2002). It seems likely that similar reasons also exist 
for the spiralling of vessels in the endometrium. Examination of uterine vessel 
cross sections shows that the vessels are not sph'alling around cores of the 
interweaving smooth muscle fibres. The coils of larger vessels would instead
seem to be contained within a matrix that is rich in elastin (Metaxa-Mariatou et al.
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2002). It has been postulated that the highly coiled nature of the myometriai 
arteries is designed to permit expansion of the myometriai smooth muscle as it 
hypertrophies during pregnancy (Farrer-Brown, Beilby and Tarbit 1970b;Farrer- 
Brown, Beilby and Tarbit 1970d). During pregnancy-induced hypertrophy of rat 
uterine arcuate arteries, there is an increase in arcuate vascular diameter that is 
reversed in the post-partum period (St Louis et al. 1997). The vascular pattern 
seen in these hysterectomy specimens, taken from largely multiparous women, 
would be expected to be a product of several remodelling cycles. It would seem 
likely that a balanced system of continued remodelling and maturation is requked 
for vessel development within the myometrium. Smooth coils without points of 
inflection or straight segments would be expected to develop at points in the 
system where there is a balance between radial and axial growth and local 
remodelling of vascular muscle orientation. Angiogenesis is controlled by the 
equilibrium that exists between pro- and anti-angiogenic factors such as vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF) and tumour 
necrosis factor a (TNFa) (Bikfalvi et al. 1997). Existing vessels must then mature 
under the control of other signaling molecules such as angiopoetins, platelet- 
derived growth factor (EDGE), integrins and matrix metalloproteinases, 
permitting pericyte recruitment, basement membrane formation and extracellular' 
matrix deposition to increase vessel diameter (Thurston et al. 1999). This 
maturation phase encompasses the recr-uitment of cells to form vessel walls and 
may contribute to the gradient of vessel wall density seen in normal myometrium. 
During the course of fibroid development, in which there is abnormal increase in 
muscle growth, there is accompanying dysregulation of the normal vascular* 
pattern. The small fibroids appear to lack well-developed muscularized vessels 
and show no evidence of spir alling. Although fibroid growth must be
accompanied by angiogenesis, the present data show that there is a lack of
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vascular' smooth muscle cells. This apparent lack of vascular* maturation can be 
explained by either the failure of myoblastic precursor cells to migrate into the 
tumour or the suppressive arteriogenic environment of the tumour. In the present 
work, only small fibroids were studied, and it is possible that larger, muscularized 
vessels may develop in lar'ger fibroids with time. Nonetheless, the striking 
difference in vascularization seen in small fibroids makes it likely that the 
angiogenic stimulus or anti-angiogenic profile is altered within fibroids relative to 
that occuri'ing in normal tissue development with corresponding lack of 
elongation, muscularization and spiralization (Hague et al. 2000;Poncelet et al. 
2002). Fur'therinore, there would appear* to be alterations in the distribution of 
vessels in apparently normal myometrium around the fibroid (Hamid, Daly, & 
Campbell 2003).
This study has also shown that the gradient of vessel size seen in non-fibroid 
myometrium was lost in the myometrium around the fibroid. These results ar*e 
consistent with those of Hague et al. (Hague et al. 2000) who showed increased 
expression of hypoxia-induced secretory factors, adrenomedullin and VEGF in the 
myometrium of leiomyoma-bearing uteri compared with controls. Perfusion in 
myometriai vessels around the fibroid has also been shown to be reduced by 
Hickey et al. (Hickey & Fraser 2000) who also postulate that a dysregulation of 
angiogenic factors in the myometrium is responsible for these findings. Further- 
work in this area is required to determine the initial stimulus for fibroid 
generation.
Stereological examination showing small fibroids to be relatively avascular*, with
highly vascular* pseudocapsules, may provide an explanation for the rationale for
uterine artery embolisation. Contrary to previous reports on embolisation, which
discuss the ‘hypervascular’ nature of fibroids, the present stereological analysis
suggests that although the perifibroid region has a high volume fraction of vessel
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lumen, the fibroid itself is relatively avascular. The perifibroid region is abnormal 
in vascular' organization; therefore, the term 'hyper-vascularity’ should not be 
taken to imply adequate perfusion of this zone. The vascular perifibroid regions 
are likely to correspond to the peripheral rim of well vascularized vessels seen on 
ultrasound and used as the plane of tissue dissection during myomectomy 
(Fleischer 1919). The other alternative is that these abnormal vessels ar-e on the 
venous side of the vascular- tree and correspond to the venular- ectasia fu'st 
described by Sampson in 1912 and referred to, thereafter, by Stewar't and No wale 
(Stewar-t & Nowak 1996).
Previous clinical studies have shown that embolisation has little effect on the 
normal myometrium (Siskin et al. 2000). From this study, many reasons can be 
postulated as to why the fibroid may be targeted by embolisation. One may be that 
the relatively avascular* nature of the fibroid makes it more prone to tissue 
hypoperfusion than the normal tissue. Another may be that the polyvinyl alcohol 
particles used may selectively occlude the lar'ge perifibroid vessels and hence the 
blood supply to the fibroid. Following histopathological examination of uteri that 
had previously undergone UAE, it was found that the majority of particles 
collected in the perifibroid region post-embolisation (Weichert et al. 2005). It may 
also be that the lack of large vessels within the fibroid makes it more vulnerable to 
ischaemic insult due to lack of collateral flow.
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for symptomatic fibroids.
7A.5 Conclusion
In conclusion, the results of this study suggest a gradient of vessel size, wall 
thickness and tortuosity between inner and outer myometiium. This appears to be 
lost in fibroids, leading us to postulate that vessel wall maturation stimuli or the 
precursor mural cells ai'e lacking in fibroids. This is likely to have clinical 
implications, particularly in the field of uterine artery embolisation as a treatment
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:7B.1 Introduction
The three-dimensional nature of the microvascular network on cut surfaces of 
fresh human uterns, has already been demonsti'ated recently with the technique of 
diffusion labelling (Hamid, Daly, & Campbell 2003). This highlighted the 
vascular differences between normal myometiium and fibroid tissue. In an 
attempt to take things one step further, we aimed to cairy out a study using the 
method of perfusion labelling via the uterine aiteries of fresh human uterus ex-
vivo. This technique of systemic labelling was canied out just prior to capturing
■I
images of the fresh uterine specimens with the aid of MRI. This was in the hope 
of obtaining greater detail of the microvascular network of the human uterus and 
being able to demonstrate the differences between myometriai and fibroid tissue 
with more clarity. Using such new methods of visuahsation to demonstrate uterine 
vascular- networks ex vivo may further assist in our understanding of the success 
and failure of uterine artery embolisation.
7B.2 M aterials and methods
Ethics approval was obtained prior to carrying out this prospective study. Eight
uteri (four fibroid and four normal) were obtained from women undergoing
elective hysterectomy for benign disease, in South and North Glasgow University
Hospitals NHS Tmsts. All women undergoing surgery had menorrhagia and had
not received hormonal treatment for at least six months prior to surgery.
Following hysterectomy, right and left uterine ar'teries were immediately
cannulated in turn, using paediatric umbilical catheters (Vygon, 3.5 French
Gauge). The catheters were carefully secured with a non-absorbable suture and
the uterine arterial system flushed on each side with 20ml heparinised saline
(Figure 33). This was done in the hope of removing as much blood clot from the
arterial micro vasculature as possible. The uterine specimen was then immersed in
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a bucket of noiinal saline and transferred promptly to the North Glasgow 
radiology department. Within three hours of hysterectomy, the specimen was 
removed from the saline bath and each of the uterine arteries confirmed patent 
with a further injection of 10ml heparinised saline on each side. Thereafter, the 
specimen was placed witliin a MRI machine (1.5 Tesla) used for standai'd clinical 
practice, for images to be captured by an experienced radiographer. Once 
completed, 10ml of a radiopaque contrast dye in the foiin of gadolinium 
(Omniscan, 0.5 millimoles/ml, Amersham Health) was injected into each of the 
uterine arteries and MR-angiography was then performed.
In an attempt to obtain better resolution of uterine vessels, we then went on to
;■peiform higher resolution magnetic resonance imaging of fresh uterine specimens 
(n=3). Using the technique described above, each of three uterine specimens was 
placed in turn, within a 7-Tesla magnetic resonance imager belonging to Glasgow 
Vetinaiy School research depaitment (Figures 34 and 35). The magnet’s 
designation as 7-Tesla indicates its field strength and is used for reseai'ch purposes 
only. The increased magnetic field strength of the 7-Tesla machine facilitates the 
production of highly detailed images and it was anticipated that we would obtain a 
greater level of detail from this machine, when compaied to images obtained from 
standard MRI used in routine clinical practice. In addition to gadolinium, a 
fluorescently conjugated plant lectin called Ulex Europaeus Agglutinin I [UEA- 
11), a known marker of the endothelium, was used to achieve systemic endothelial 
labelling in two of the fresh uterine specimens (Honnia, Lehto, & Virtanen 1983). 
Thus, 5ml (5 microgiams/ml) of UEA-1 tetramethykhodamine isothiocyauate 
(TRITC) (Vector Ltd., Peterborough, UK) was injected into each of the uterine 
arteries after an initial flush with saline. Once again, T1 and T2-weighted images 
were captured; these were then image processed to create high intensity 
projections.
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Following MRI, randomly biopsied tissue (approximately 3-4mm in depth) from
, . ■ ■inner to outer myometrium, were taken from the two uterine specimens injected 
with the fluorescent lectin. Each piece or block of uterine tissue was then mounted 
on to a microscope slide after washing for five minutes in phosphate buffered
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!saline (PBS). By binding to vascular endothelial cells, the fluorescent lectin facilitated visualisation of the vaseulai' network on the cut surface of the utems 
(Figure 36). UAE-1 absorbs blue light and thus using blue light with a 
microscope equipped with epi-illumination, images were captured with the aid of 
a digital camera (Nikon). These images were then processed post-capture, using 
Adobe Photoshop 7.
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Figure 33
Specimen of fresh human uterus -  both uterine arteries cannulated in preparation 
for gadolinium enhanced MRI
Figure 34
Specimen of fresh human uterus placed in an open plastic bottle -  awaiting 
insertion into 7 Tesla MRI
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Figure 35
7 Tesla MRI
Figure 36
Cut surface of fresh human uterus perfused with a fluorescent lectin
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7B.3 Results
Images obtained after standard MR-angiography of fresh uterine specimens 
perfused with gadolinium were very variable in quality. Unfortunately, in four out 
of the eight specimens, we failed to demonstrate the vascular- tree of the utems. 
However, it was possible to demonstrate the tortuous vasculature of the utems in 
some cases (Figure 37). Whilst these images confirmed that it was possible to 
display the vascular network of the utems ex-vivo using standard MR- 
angiography, we were unable to show a level of detail that had previously been 
anticipated, hi addition, it was not possible to distinguish between fibroid and 
normal myometriai vasculature.
Higher resolution MR imaging of human utems using the 7-Tesla machine was 
also disappointing as we did not obtain better resolution of uterine 
microvasculature. Instead of the thin spirals that we expected, vessels were seen 
as “fat wiggly sausages” (figure 38). We did, however, obtain better resolution of 
the non-vascular components of fibroids. The heterogeneity of these lesions could 
be clearly demonstrated as well as the lack of presence of lar'ge vessels (figure 
39).
Images obtained from microscopy of cut surfaces of fresh utems perfused with the 
fluorescent lectin demonstrated the myometriai vascular' network in 3D (figures 
40A and B).
Figure 37
MR-angiography of fresh human uterus perfused with gadolinium
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Figure 38
High resolution MR images after rendering of T1-weighted minimum intensity 
projections. A. Large surface vessels of a pedunculated fibroid (F) and distorted 
uterine body (U). B. Distribution of large vessels in mid-slice of myometrium
. . .
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Figure 39
High resolution MR image of a T2-weighted cross-section of a large pedunculated 
fibroid - ( C)  is a highly cellular area. Note the heterogeneity of non-vascular 
components of the fibroid and the lack of large vessels seen in the tumour
Figures 40A and B
Perfusion labelling of human uterus demonstrating human myometriai 
microvascular pattern in 3D
B
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%7B.4 Discussion
Experimental work using perfusion methods in combination with standai'd and 
high resolution MRI, has confirmed that it is possible to visualise uterine vaseulai*
networks ex-vivo. However, we were unable to obtain better resolution of uterine
. .
■micro vasculature, as had been anticipated. One of the reasons for this is likely to 
be artefact, perhaps caused by air embolism, blood clot or a combination of both.
In addition, it was not always possible to perfuse the uterus beyond the level of 
the main uterine ai'tery. Interestingly, the pathologist examining the uterine 
specimens which had undergone uterine aiterial flushing followed by perfusion 
with gadolinium plus or minus the fluorescent lectin, found the uteri to be 
paiticulai'ly white and avasculai* in appear ance. Both standard and high resolution 
MR-angiography appear’ to have their limitations in terms of demonstr ation of 
uterine and fibroid vasculature although high resolution MRI demonstrated non- 
vasculai' components of the uterus in great detail. The images of uterine 
micro vasculature that we obtained are still not equivalent to the traditional 
angiography techniques that Far'rer-Brown and colleagues performed on thin 
uterine slices. Nonetheless, our new methods of visualisation have facilitated a 
better understanding of tissue and fibroid structure as well as the vascular* patterns 
of both myometriuiu and fibroids.
I
7B.5 Conclusion
It is possible to demonstrate the vascular* network of the uterus ex-vivo, using 
perfusion and systemic labelling techniques in conjunction with both standar'd and 
high resolution MRI. In addition, high resolution MRI facilitates demonstration of
4
non-vascular' components of the uterus and fibroids with a high level of detail.
This study demonstrates the vascular* patterns seen in human myoruetrial and
3
      .
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fibroid tissue, and to some extent, the differences between normal and diseased |  
uterine tissue. 3
1
I
I
Chapter 8
Final Conclusions
153
18.1 SummaryWe have shown that UAE is effective in reducing objective MBL and uterine 
volume up to 48 months and 6 months after treatment, respectively (chapter 2). 
This is the only published study to date, which evaluates the effect of UAE on 
MBL objectively. Whilst this study is small and does not compare UAE to other 
uterine-sparing modalities, it is useful to have objective measures of outcome 
when evaluating a new technique in the early stages of its introduction to clinical 
practice. In addition, having objective evidence to support the use of a relatively 
new treatment can be very useful when counselling women about the therapeutic 
options available to them.
We have also demonstrated that UAE is associated with a significant 
improvement in health status (as assessed by the SF 36) which is maintained up to 
60 months post-embolisation (chapter 3). This is in keeping with other recent 
studies evaluating the effect of UAE on HRQoL (Scheurig et al. 2006). Using a 
tool such as the SF 36 allows us to demonstiate that overall health, and not just 
menstrual symptoms, improves after embolisation.
Data from obseiwational studies is useful, but one needs to comp aie a new therapy
to the gold standard treatment before introducing it into routine clinical practice.
The REST trial addresses this issue (chapter 5). This study concluded that there is
no significant difference between surgery and embolisation in quality of life at
one yeai-, in women with symptomatic fibroids. Embolisation was associated with
a significantly shorter hospital stay and recovery time whilst surgery was
associated with significantly better symptom scores at one yeai’. The trial reported
similai* complication rates after both interventions and in paiticulai', highlighted
the need to monitor women post-embolisation for complications which do not
always present iimnediately after the embolisation procedure. It also reported a
treatment failure rate of 9% at one year in the embolisation aim of the trial and
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commented that secondaiy procedures for persistent or recurrent symptoms were 
requned in some cases, after one yeai\
It was difficult to extr apolate meaningful conclusions from the comparison of 
UAE to myomectomy in the REST trial, as only a small number of women 
underwent myomectomy. Other studies comparing the clinical results of UAE and 
myomectomy in women planning future pregnancy have not been prospective 
(Broder et al. 2002;Goldberg et al. 2004;Razavi et al. 2003) whilst one 
prospective randomised controlled trial compaiing the two therapies was unable to 
evaluate the reproductive outcomes of both treatments although it did suggest drat 
embolisation and myomectomy are clinically effective in most cases and not 
associated with a significant number of serious complications (Mam et al. 2006).
Thus longer term data from prospective compar ative trials involving larger 
numbers of women is requir ed in order to evaluate the effects of embolisation 
versus myomectomy on reproductive function and perinatal outcomes in women 
with symptomatic fibroids. Until this data is available, it remains uncertain as to 
whether UAE or myomectomy is the best option for women who wish to retain 
their fertility.
We experienced successful pregnancy outcomes after UAE although it remains
unclear whether or not pregnancy outcomes are affected by the procedure. Less
than 200 pregnancies have been reported in the literature to date. Whilst there
have been good pregnancy outcomes reported after embolisation, the rates of
miscaiTiage, pre-term delivery, caesai'ean section and post-partum haemorrhage
appeal' to be increased, when compai'ed to the general obstetric population (Huang
et al. 2006;Pron et al. 2005;Walker & McDowell 2006). Demographics such as
increased maternal age of the women in the study population may partly explain
these findings; advanced age not only reduces the chances of successful
conception, but also increases the chances of adverse obstetric outcomes. Thus
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further data on pregnancy outcomes is still required in order for us to be able to 
counsel women appropriately on this point prior to undergoing UAE.
The risk of premature ovaiian failure after embolisation remains an important 
issue for women considering UAE prior to completion of their family. The rate of 
ovaiian failure was relatively high in our group of predominantly peri-menopausal 
women (chapter 2), but in general, permanent amenorrhoea or the menopause 
occurs in up to 15% of women above the age of 45 years and in less than 1% of 
younger women. Several studies have assessed the impact of embolisation on 
ovaiian function, all of which have measured follicle-stimulating honnone (FSH) 
before and after UAE (Ahmad et al. 2002;Healey et al. 2004;Spies et al. 2001).
These studies did not show a significant difference in baseline and post- 
embolisation FSH values. It should, however, be borne in mind that amenorrhoea 
or the menopause is a measure only of severe ovarian dysfunction and die number 
of women with milder forms of ovarian damage is likely to be substantially higher 
than we estimate. Women, therefore, should be thoroughly counselled about the 
important potential side effect of ovaiian failure and its consequences, prior to 
undergoing embolisation.
We are well acquainted with the option of UAE as a treatment of symptomatic 
fibroids in pre-menopausal women. However, it has been thought to be of little 
benefit in postmenopausal women, based on the theory that fibroid tumour 
shiinkage occurs at this time in a woman’s life, as a result of the absence of 
ovaiian hormonal stimuli. Thus all women in our studies were pre-menopausal.
Recently, however, a reti'ospective study has been carried out evaluating the effect 
of UAE in postmenopausal women with fibroid-related bulk symptoms (Chrisman 
et al. 2007). This study reported a significant reduction in fibroid volume and 
improvement in bulk-related symptoms up to a period of 24 months after
..IV
treatment. The authors concluded that UAE is a viable treatment option in
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carefully selected post-menopausal women with known fibroids associated with 
bulk-related symptoms. It is therefore worth considering embolisation as a 
tieatment option in women with symptomatic fibroids, both pre- and 
postmenopausal, after caieful evaluation of their clinical symptoms.
Studies have been carried out recently to determine the paiticular baseline fibroid 
tumour chamcteristics which predict outcome for UAE. Chapter 2 concluded that 
UAE is associated with a significant reduction in uterine volume (and thus fibroid 
shrinkage) at 6 months post-treatment (median reduction -  41%). However, there 
was no correlation between the degree of fibroid shrinkage and change in 
objective menstrual blood loss measurement for individual patients at that time. 
Spies et al reported that a greater baseline fibroid volume results in less shrinkage 
after UAE and overall, the lai'ger the dominant fibroid prior to embolisation, the 
less volume reduction after UAE and the greater likelihood of patient 
dissatisfaction with the outcome of embolisation (Spies et al. 2002b), Other 
studies report an association between fibroid size, location and MR signal 
intensity with outcome (Bum et al. 2000;McLucas, Adler, & Penella 1999). A 
submucosal location appeal's to be associated with a better outcome in the short 
tei*m. In addition, a high fibroid signal intensity on T1-weighted MR images 
(thought to result from haemorrhagic necrosis and the presence of blood 
breakdown products) was strongly predictive of a poor response to UAE whilst a 
high signal intensity on T2-weighted images (thought to be due to increased 
fibroid cellularity and/or vascularity) was predictive of a good response to UAE. 
Interestingly, the degree of gadolinium enhancement did not correlate with fibroid 
volume reduction. It should be emphasised that these studies have their limitations 
and there continues to be a need for further research into the effect of baseline 
uterine/fibroid size and location on clinical outcomes as well as the impact of
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fibroid volume reduction and degree of de vascularization on both short and long 
teiin outcomes of UAE.
The treatment failure rate after UAE was 9% at one year in the REST trial with a 
further 10% requiring a secondary intervention after one yeta’s follow up. These 
findings not only highlight the need for longer term follow up of women post- 
embolisation, but also encourage us to think about the reasons for treatment 
failures and the options for secondaiy procedures. The latter may be requh’ed for 
women who have no improvement of symptoms after UAE or for those women 
who have a recuixence of symptoms, usually due to increasing dominant fibroid 
size or increasing number of fibroids. Within the setting of the REST trial, most 
secondary procedures were hysterectomies. However, in the future, we perhaps 
need to consider repeat UAE in more women. Yuosefi et al caiiied out a study of 
24 women who underwent repeat embolisation for recurrent or persistent fibroid- 
associated symptoms (Yousefi et al. 2006). MR-angiography was performed prior 
to the repeat procedure. Whilst this study was small and short term, the authors
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reported that repeat UAE is effective in contiolling symptoms in the majority of 
patients, although embolisation of the ovarian aiteries is often required. 
Complications were infrequent, but they concluded that further studies are 
requhed in order to establish the safety and efficacy of repeat embolisation.
The risks of major complications such as pelvic sepsis and emergency 
hysterectomy were low in our group of women undergoing UAE and these rates 
are comparable to those quoted in other published literature. Chapter 6, however, 
highlights the need for us to be aware of the potential for late presentation of 
infective complications after UAE.
We found that uncomplicated UAE is associated with a significant rise in WCC, 
CRP and IL-6, with peaks occurring thi’ee days post-embolisation followed by a 
reduction and normalisation of levels at one month after UAE (chapter 4). No
coiTelation was found between pain scores and individual inflammatory marker 
levels at that time. With the exception of one individual, inflammatory mediator 
levels did not rise during the time period in which a proportion of our group of 
women complained of clinical symptoms in keeping with the post-embolisation
response to UAE and its moleculai* basis requires further evaluation and we still 
need a better understanding of fibroid pathogenesis and uterine vasculature, in
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:"Asyndrome. The results of this study are not what we expected. An alternative 
explanation therefore must exist for the pathophysiology of the post-embolisation 
syndrome, a syndrome which must be more complex than we previously thought. 
The differences that have been obseiwed between normal and diseased (fibroid) 
uterine tissue have been exploited clinically by uterine aitery embolisation for the 
treatment of symptomatic fibroids. Examination of the uterine vascular' network in 
greater detail has confmned that such differences exist (chapter 7A and B). We 
have shown that a gradient of vasculai'ity exists within the myometrium and also, 
that there are no mature vessels within fibroids. With increasing knowledge and 
understanding of uterine and fibroid microvasculature, we may, in the future, be 
able to predict with more accuracy, cases that ai'e likely to be successful and those 
that ar*e likely to fail, after UAE.
In final conclusion, UAE appeal's to be a safe and efficacious method of treatment 
for women with symptomatic fibroids, in the short and mid-term. More evidence, 
however, is required on long term outcomes following UAE, with particular 
attention to complications, treatment failures and fibroid growtli / recurrence after 
embolisation. Further long term data is also needed regarding the effects of UAE 
on fertility and pregnancy. In addition, more prospective compaiative studies ai'e 
required to compare embolisation to the various techniques of hysterectomy. We
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also need to compare and evaluate tire outcomes of embolisation and other 
uterine-sparing modalities, in paiticular, myomectomy. The inflammatory
:
order to farther develop therapeutic options for symptomatic fibroids, and 
understand the exact underlying mechanisms of treatments such as UAE.
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8.2 Future work possibilities
1. Long term follow up of patients recmited into the REST trial with particulai' 
attention to relapse and recurrence of symptoms, long term complications, 
treatment reintervention, fertility and pregnancy outcomes.
2. Further investigation of the inflammatory response to UAE and the aetiology of 
the post-embolisation syndrome, using alternative biomarkers to those used in our 
study
3. Further analysis of uterine and fibroid microvasculature with more research into 
the detection and use of biological maikers which distinguish ai’teries form veins.
4. Research into the use of animal models for uterine fibroid and UAE studies
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Appendix 1
Short Form 36
The following questions ask for your views regarding your health and 
how you feel about life in general. Answer all the questions, if you are 
unsure then think about your overall health and give the best answer 
you can.
1/ In general, would you say your health is ?
(circle one)
excellent 1
very good 2
good 3
fair 4
poor 5
2J Compared to four months ago, how would you rate your general health 
now ?
much better
somewhat better 
about the same 
somewhatworse 
much worse
3/ The following questions are about activities you might do during a 
typical day. Does your health limit you in these activities ? If so, how 
much ?
(circle one number for each question)
YES, YES, NO, NOT
ACTIVITIES LIMITED LIMITED LIMITEDA LOT A LITTLE AT ALL
a / vigorous activities, such as running, 
lifting heavy objects or strenuous sports 
?
1 2 3
b / moderate activities such as moving a
table, hoovering ,bowling or golf ? 1 2 3
c / lifting or carrying groceries ? 1 2 3
d /  chmbing several flights of stairs ? 1 2 3
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e /  climbing one flight of stairs ? 
f /  bending, kneeling or stooping ? 
g / walking more than a mile ? 
h /  walking half a müe ?
1/ walking 100 yards 
j /  bathing or dressing yourself
V  During the past 4 weeks , have you had any of the following problems 
with your work or other regular daily activities as a result of vour physical 
health ?
a / cut down on the amount of time you 
spent on work or other activities ?
b / accomplished less than you would 
have liked ?
c / were limited in the kind of work or 
activities ?
d /  had difficulty performing the work 
or other activities (e.g. it took extra 
effort )?
YES NO
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5/ During the past 4 weeks , have you had any of the following problems 
witli your work or other regular daily activities as a result of anv 
emotional problems ( such as feeling depressed or anxious)?
YES NO
a / cut down on the amount of time you
spent on work or other activities ? 1 2
b / accomplished less than you would 1 2
have liked ?
c / didn't do work or other activities as
carefully as usual ? 1 2
6/ During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities with 
friends, family or groups ?
(chcle one ) 
not at all 1
slightly 2
moderately 3
quite a bit 4
extremely 5
7/ How much bodily pain have you had in the past 4 weeks ? (circle one )
none 1
very mild 2
mild 3
moderate 4
severe 5
very severe 6
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8/ During tlie past 4 weeks, how much did pain interfere with your normal 
work
( including both work outside the home and housework ) ?
not at all 1
a little bit 2
moderately 3
quite a bit 4
extremely 5
9/ These questions are about how you feel and how things have been with 
you during the past 4 weeks.
For each question, please give the one answer that comes closest to the
way you have been feeling. ......
(circle one number for each question)
HOW MUCH TIME All of Most of A good Some of A little None of
IN the time the time bit of the time of the the time
THE LAST 4 WEEKS the time time
a /  did you feel full of 1
hfe?
b / have you been 1
nervous ?
c / have you felt so 
down in the dumps 1
that nothing could 
cheer you up ?
d /  have you felt calm 1
and peaceful ?
e /  did you have a lot 1
of energy ?
f/ have you felt 1
downhearted and low 
?
g / did you feel worn 1
out ?
h /  have you been 2
181
happy ?
1/ did you feel tired ?
10/ During the past 4 weeks, how much of the time has your physical 
health or emotional problems interfered with your social activities ( hke 
visiting with friends, relatives, etc.) ?
all of the time 1 
most of the time. 2 
some of the time 3 
a htüe of the time 4 
none of the time.... 5
11/ How true  or FALSE is each of the following statements for you 
(circle one number for each question)
DEFINITELY MOSTLY DON'T MOSTLY DEFINITELYTRUE TRUE KNOW FALSE FALSE
a / I seem to
get ill more 1 2 3 4 5
easily than
other people
b / I am as
healthy as 1 2 3 4 5
anybody I 
know
c/ I expect my 
health to get 
worse
d /  My health 
is excellent
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